[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 110
1. Fornari G, Artusio E, Mairone L, Airoldi M, Bongioannini G, Amasio E, Rosmino C, Gabriele P: Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori; 2002 Nov-Dec;88(6):489-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
  • AIM AND BACKGROUND: To evaluate feasibility of neoadjuvant chemotherapy (NA-CT) followed by CT + radiotherapy (RT) in locally advanced or unresectable head and neck squamous cell carcinoma (HNSCC).
  • Sites of disease: oral cavity, 18.2%; oropharynx, 40.9%; hypopharynx, 18.2%; larynx, 4.6%, multiple sites, 18.2%.
  • Stage: III, 4.6%; IVA, 63.6%; IVB, 31.8%.
  • Responders received definitive radiotherapy with concurrent carboplatin (35 mg/m2/day from days 1 to 5 in weeks 1, 3, 5 and 7) and paclitaxel (50 mg/m2 on days 10, 24 and 38).
  • 97% of planned chemotherapy cycles were administered.
  • Median dose of RT was 70.2 Gy on T/N+ and 54 Gy on NO.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy / adverse effects. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant / adverse effects. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597144.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Rapoport A, Botelho RA, Souza RP, Cavalcanti SM, Furlam S, Tornin Ode S, Souza TR: The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. Braz J Otorhinolaryngol; 2008 Jan-Feb;74(1):74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer.
  • The involvement of pre-epiglottis space can change the indication for partial laryngeal resection.
  • AIM: The aim of this study was to evaluate inter-observer and intra-observer agreement by means of computed tomography analysis regarding the involvement of the pre-epiglottis space (PES) from carcinoma of the upper aerodigestive tract and its relation with therapeutic planning.
  • MATERIALS AND METHODS: Retrospective study of ninety-five computed tomography exams of patients with squamous cell carcinoma, from 1990 to 2004, were selected and evaluated; 87 were males and eight females, with ages ranging from 32 to 73 years.
  • Imaging results were analyzed twice by three radiologists, individually, without any previous knowledge of the clinical stage.
  • No patient had received any previous treatment up to the moment of imaging examination, such as surgery, chemotherapy or radiotherapy.
  • CONCLUSIONS: After a general Kappa Index of 0.72, the results suggest a substantial agreement in the involvement of the PES by means of computed tomography analysis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Epiglottis / pathology. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Observer Variation. Reproducibility of Results. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392505.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, Rosenthal DI, Gillison M, Forastiere AA: Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol; 2007 Sep 1;25(25):3971-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
  • This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (OP) cancer patients.
  • PATIENTS AND METHODS: Eligibility required resectable stage T2N+, or T3-T4N0-3M0 biopsy-proven squamous carcinoma, age at least 18 years, PS 0 to 2, good organ function, and no prior chemotherapy or radiation.
  • Treatment was induction paclitaxel 175 mg/m(2) and carboplatin area under the concentration-time curve (AUC) 6 for two cycles every 21 days followed by concurrent paclitaxel 30 mg/m(2) every 7 days with 70 Gy if no evidence of tumor progression.
  • RESULTS: One hundred five of 111 patients (36 larynx, 69 OP) were eligible.
  • No patient progressed while receiving chemotherapy.
  • Organ preservation was 81% at 2 years after completion of therapy (larynx 74%, OP 84%).
  • Thirteen patients required primary-site salvage surgery (seven larynx, six OP), and six of these have progressed and died (three larynx, three OP).
  • Thirteen patients developed distant metastases (seven larynx, six OP; P = .02) and 10 of 36 larynx and 11 of 69 OP patients have died as a result of their disease.
  • Two-year survival is 76% (63% larynx v 83% OP).
  • CONCLUSION: A high organ preservation rate was obtained with this regimen for OP but not for larynx patients.
  • Toxicity was low, and induction chemotherapy did not preclude delivery of concurrent chemoradiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bridged Compounds / administration & dosage. Chemotherapy, Adjuvant. Deglutition Disorders / etiology. Deglutition Disorders / prevention & control. Female. Follow-Up Studies. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pharyngectomy. Platinum / administration & dosage. Radiotherapy, Adjuvant. Recovery of Function. Salvage Therapy. Speech Disorders / etiology. Speech Disorders / prevention & control. Taxoids / administration & dosage. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane; 49DFR088MY / Platinum; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Teknos TN, Cox C, Barrios MA, Chepeha DB, Bradford CR, Fisher SG, Wolf GT: Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope; 2002 May;112(5):844-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.
  • BACKGROUND: The purpose of this study was to retrospectively investigate tumor angiogenesis as a predictive marker for response to neoadjuvant chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma.
  • METHODS: A total of 332 patients with stage III (188 patients) or stage IV (144 patients) squamous cell carcinoma of the larynx were entered in the prospective trial conducted by the Department of Veteran Affairs Laryngeal Cancer Study Group.
  • Of this patient population, 20 pretreatment biopsy specimens were available from the chemotherapy arm for immunohistochemical analysis of Factor VIII expression.
  • RESULTS: The patients who had a partial response (>50% decrease in tumor volume) or complete response to chemotherapy had a mean value of 20.90 (+/- 8.09 standard deviation [SD]) blood vessels per HPF.
  • Those who did not respond to chemotherapy and thus required a total laryngectomy had a mean value of 32.99 (+/- 10.10 SD) vessels per HPF.
  • Kaplan-Meier survival curve analysis also revealed that patients with vessel counts above the mean tended to have poorer survival than those below the mean regardless of treatment selection.
  • The most-vascular tumors, those greater than 1 SD above the mean, had a statistically significant difference in survival and laryngeal preservation (P = .0345).
  • CONCLUSIONS: These results indicate that tumor angiogenesis, as measured by number of vessels per HPF, was associated with decreased responsiveness to chemotherapy and radiation for larynx preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / blood supply. Laryngeal Neoplasms / blood supply. Laryngectomy. Neoadjuvant Therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Factor VIII / analysis. Female. Fluorouracil / administration & dosage. Humans. Larynx / pathology. Male. Microcirculation / drug effects. Microcirculation / pathology. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Salvage Therapy. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150616.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-27-8 / Factor VIII; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Zimmer-Nowicka J, Kaczmarczyk D, Chudobiński C, Kubiak R, Niedźwiecka I, Morawiec-Bajda A: [Diagnostic problems in a case of the pyriform sinus carcinoma in a man]. Otolaryngol Pol; 2008;62(4):442-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems in a case of the pyriform sinus carcinoma in a man].
  • Despite a use of many diagnostic tools to assess the stage of the carcinoma of hypopharynx and larynx various problems can still arise.
  • A 45 years old man was admitted with an initial diagnosis of carcinoma of the hypopharynx with metastases to neck lymphnodes (Tin situ N1).
  • Computed tomography of the neck revealed pathologic remodeling of the thyroid cartilage.
  • An oncologist decided to commence a chemotherapy.
  • After 4 cycles of chemotherapy a second CT scan revealed a suspected neoplastic infiltration of the cricoid and thyroid cartilages.
  • After that the patients was disqualified from both radio- and chemotherapy.
  • The consulting laryngologist did not find any pathologies in the larynx and hypopharynx.
  • The positron emission tomography imaging found a suspected site 11 mm in diameter situated in front of the carotid vessels.
  • The neoplastic infiltration of the larynx was not confirmed.
  • We are of the opinion that in the presented case the erroneous interpretation of the CT scan was a likely consequence of the improper setting of a window of brightness and contrast.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiography. Hypopharynx / pathology. Hypopharynx / radiography
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837220.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


6. Sanabria A, Domenge C, D'cruz A, Kowalski LP: Organ preservation protocols in developing countries. Curr Opin Otolaryngol Head Neck Surg; 2010 Apr;18(2):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Conservative surgical procedures, radiotherapy and chemoradiotherapy can all be considered in organ preservation strategies for patients with head and neck squamous cell carcinoma.
  • RECENT FINDINGS: The results of most organ preservation studies are focused on survival and larynx preservation, but an evaluation of quality of life and function of the organ is still lacking.
  • In the present review we consider the possible problems associated with the application of organ preservation strategies in developing countries in some critical areas: advanced stage, comorbidities, nutritional status, long distance to travel, availability of chemotherapy and radiotherapy facilities, tolerance, adherence to protocol standards and expertize in performing salvage surgery.
  • Recent publications strongly suggest that chemoradiation should not be indicated in all patients with advanced laryngeal and hypopharyngeal cancer, but that an individualized treatment strategy should be recommended.
  • SUMMARY: Organ preservation treatments depend on factors related to the physician and the institutions providing healthcare, and also on patients and health systems and socioeconomic factors that make it impossible to extrapolate these results.
  • [MeSH-major] Clinical Protocols / standards. Developing Countries. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Salvage Therapy / standards. Salvage Therapy / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216217.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


7. Amdur RJ, Mendenhall WM, Stringer SP, Villaret DB, Cassisi NJ: Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus. Head Neck; 2001 May;23(5):353-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus.
  • PURPOSE: To report long-term results using radiotherapy with or without a planned neck dissection for T1-T2 carcinoma of the pyriform sinus.
  • Cause-specific survival rates at 5 years were as follows: stage I-II, 96%; stage III, 62%; stage IVA, 49%; and stage IVB, 33%.
  • The absolute survival rates were as follows: stage I, 57%; stage II, 61%; stage III, 41%; stage IVA, 29%; and stage IVB, 25%.
  • Moderate to severe long-term complications developed in 12% of patients.
  • CONCLUSIONS: RT alone or combined with a planned neck dissection resulted in local control with larynx preservation in a high proportion of patients.
  • The addition of adjuvant chemotherapy is unlikely to improve the probability of organ preservation, but might improve locoregional control for patients with advanced nodal disease.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Larynx / surgery. Neck Dissection. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Complications. Salvage Therapy. Time. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc.
  • (PMID = 11295808.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Oyama K, Hirosawa H, Ito H, Fukushima W, Masutani H, Kadoya N, Izumi R, Hirono T: [A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2000 Jun;27(6):899-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil].
  • We have experienced a case of advanced esophageal carcinoma successfully treated with chemoradiation therapy together with low-dose cisplatin and 5-fluorouracil, having only minor toxicity.
  • Cervical esophageal carcinoma was found to have invaded the larynx through endoscopy, and invasion to thyroid gland and trachea was suspected from a cervical CT.
  • We diagnosed the condition as advanced esophageal carcinoma (A2N(-)M0Pl0 Stage III).
  • We then treated the patient by chemoradiation therapy.
  • After the treatment, the carcinoma could not be detected by CT and endoscopy, and endoscopic biopsy revealed there were no active carcinoma cells.
  • The side effects of the therapy were very mild, therefore the patient could be discharged after a short time.
  • No evidence of a tumor relapse was found 5 months after the therapy.
  • We treated 4 patients with esophageal carcinoma using the same regimen, and the results of the therapy were 2 CR, 1 PR, and 1 PD, with an overall response rate of 75%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10897218.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


9. Leethanakul C, Patel V, Gillespie J, Shillitoe E, Kellman RM, Ensley JF, Limwongse V, Emmert-Buck MR, Krizman DB, Gutkind JS: Gene expression profiles in squamous cell carcinomas of the oral cavity: use of laser capture microdissection for the construction and analysis of stage-specific cDNA libraries. Oral Oncol; 2000 Sep;36(5):474-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles in squamous cell carcinomas of the oral cavity: use of laser capture microdissection for the construction and analysis of stage-specific cDNA libraries.
  • Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer among men in the developed world affecting the oral cavity, salivary glands, larynx and pharynx.
  • Utilizing tissue from patients with HNSCC, we sought to systematically identify and catalog genes expressed in HNSCC progression.
  • Here, we demonstrate the successful use of laser capture microdissection for procuring pure populations of cells from patient tissue sets comprised of oral squamous cell carcinomas (OSCCs) and matching normal tissue.
  • The RNA was used for the synthesis of blunt-ended, double-strand complementary DNAs (cDNAs) by oligo (dT)-mediated reverse transcription, followed by addition of linkers.
  • These results demonstrate that high quality, representative cDNA libraries can be generated from microdissected OSCC tissue.
  • Furthermore, these finding suggest the existence of at least 132 novel genes expressed in our cDNA libraries, which may have a role in the pathogenesis of HNSCC, and may represent novel markers for early detection as well as targets for pharmacological intervention in this disease.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA, Complementary / genetics. Dissection / methods. Gene Expression Profiling / methods. Gene Library. Lasers. Mouth Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10964057.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Neoplasm
  •  go-up   go-down


10. Franchin G, Vaccher E, Gobitti C, Minatel E, Politi D, Talamini R, Di Gennaro G, Savignano G, Trovò MG, Tirelli U, Barzan L: Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncol; 2005 May;41(5):526-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
  • A prospective phase II trial was carried out to evaluate an accelerated chemotherapy (CT) regimen followed by hyperfractionated radiation therapy (RT) in previously untreated Stage III-IV, operable (total laryngectomy), head and neck cancer patients.
  • Sixty patients received the planned RT-CT treatment.
  • The accelerated CT-RT regimen achieves a high rate of larynx preservation albeit with considerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Mouth Mucosa / radiation effects. Prospective Studies. Radiation Injuries / etiology. Radiotherapy / adverse effects. Stomatitis / etiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878759.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Abitbol A, Abdel-Wahab M, Lewin A, Troner M, Rodrigues MA, Hamilton-Nelson KL, Markoe A: Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):942-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
  • PURPOSE: To determine the toxicity and efficacy of concurrent 5-fluorouracil (5-FU), cisplatin, and paclitaxel (Taxol) and hyperfractionated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
  • Eligible patients had Stage III or IV head-and-neck squamous cell carcinoma arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx.
  • The plan of treatment consisted of hyperfractionated radiotherapy (74.4 Gy at twice daily fractions of 1.2 Gy).
  • Chemotherapy was given on Weeks 1, 5, and 8 as follows: 5-FU at 750 mg/m2 as a constant infusion for 24 h for 3 days; cisplatin at 50 mg/m2 in 250-500 mL D5 0.5 NS or NS infusion during 2-4 h, and paclitaxel at 70 mg/m2 infused in 500 mL NS during 3 h.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cisplatin / therapeutic use. Dose Fractionation. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Paclitaxel / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12095561.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Medina JA, Rueda A, de Pasos AS, Contreras J, Cobo M, Moreno P, Benavides M, Villanueva A, Alba E: A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol; 2006 Apr;79(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: This phase II study evaluated the efficacy and toxicity of weekly cisplatin along with concomitant boost accelerated radiation regimen in patients with locally advanced unresectable head and neck carcinoma.
  • MATERIAL AND METHODS: A total of 94 patients (median age, 58 years) with UICC stage III (n = 19) and IV (n = 75) cancer of the oropharynx, larynx, hypopharynx and oral cavity were included.
  • Patients received radiotherapy with a concomitant boost scheme (1.8 Gy on days 1-40 and 1.5 Gy boost on days 25-40 with a total dose of 72 Gy) and concurrent cisplatin, 40 mg/m(2) weekly, for the first 4 weeks.
  • RESULTS: Most patients (95%) received both radiation and chemotherapy according to protocol.
  • With a median follow of 41 months, median overall survival and time to progression were 27 and 25 months, respectively.
  • CONCLUSIONS: Concomitant boost accelerated radiation plus concurrent weekly cisplatin is a feasible schedule in patients with locally advanced unresectable head and neck carcinoma, with acceptable toxicity and survival data.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Feasibility Studies. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Spain. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626826.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ, Stack BC Jr, Needles B, Boyd JH: Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999. Cancer; 2001 Mar 1;91(5):940-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
  • BACKGROUND: After standard therapy for advanced head and neck carcinoma, 5-year survival rate is less than 50%.
  • Our purpose was to develop a new treatment for advanced head and neck carcinoma by using preoperative chemotherapy.
  • METHODS: Between 1994 and 1999, 62 consecutive patients with newly diagnosed head and neck carcinoma were treated with paclitaxel and carboplatin induction chemotherapy.
  • Chemotherapy was administered every 21 days with 3 courses of paclitaxel (150-265 mg/m(2)) and carboplatin at a dose calculated using the Calvert formula area under the curve of 7.5.
  • Patients who achieved complete or partial response at the primary received definitive radiation to the primary tumor and those with lymph node disease received neck dissection followed by radiation to the regional lymph nodes.
  • Seventy-four percent had Stage IV (according to the 5th edition of American Joint Committee on Cancer Staging manual) disease.
  • The median duration of follow-up from initiation of chemotherapy was 64 weeks (range, 1-272 weeks).
  • Responses were observed at all anatomic sites: oropharynx 20 of 33 (61%); hypopharynx 8 of 12 (67%); and larynx 13 of 17 (76%).
  • Kaplan-Meier estimates of overall survival (OS), at 230 weeks, were significantly better in Stage IV oropharynx/hypopharynx responders than nonresponders (55% vs. 27%; P = 0.04).
  • Organ preservation was achieved in 28 of 62 (45%) of patients at all anatomic sites: oropharynx 39%, hypopharynx 42%, larynx 59%.
  • The response rate was encouraging considering most patients were Stage IV.
  • Chemotherapy response identified a group with improved prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11251945.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Herchenhorn D, Dias FL, Ferreira CG, Araújo CM, Lima RA, Small IA, Kligerman J: Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation. ORL J Otorhinolaryngol Relat Spec; 2008;70(6):381-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation.
  • HYPOTHESIS: The combination of chemotherapy and radiotherapy is a standard nonsurgical treatment for locally advanced laryngeal cancer.
  • Nevertheless, there are no validated markers to predict the outcome of nonsurgical therapies.
  • Prognostic factors such as stage, age, performance status, number of chemotherapy cycles, radiotherapy dose, stage VIb disease, and previous tracheotomy were analyzed using the Cox's proportional hazard model.
  • PATIENTS AND METHODS: Patients with stage III/IV laryngeal carcinoma were prospectively selected.
  • Treatment consisted of cisplatin 100 mg/m(2) every 3 weeks for 3 cycles, radiotherapy to a total dose of 70.2 Gy and salvage surgery.
  • RESULTS: Forty-nine patients were analyzed; tracheotomy was performed in 12 patients (24.5%) before therapy.
  • CONCLUSIONS: Previous tracheotomy is a negative prognostic factor for patients submitted to chemotherapy combined with radiotherapy and should be considered as a negative clinical prognostic factor in the selection of patients for more aggressive treatment strategies.
  • [MeSH-major] Airway Obstruction / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Tracheotomy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18984974.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Yu F, Dong YL, Zu ZJ, Zhan XD, Shu JH, Yang JS, Han GS, Lu LC, Zhang K, Sun HJ, Ren KJ: [Surgical management of hypopharyngeal cancer]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Aug;38(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the preservation of laryngeal function for the patients with hypopharyngeal cancer.
  • Radiotherapy (37 cases), operation only (56 cases) and the combined treatment (operation plus radiation or chemotherapy, 200 cases) were adopted.
  • RESULTS: The 5 year survival rates of patient with laryngeal function preserved and no laryngeal function preserved were 51.3%, 47.6% (for stage III); 40.4%, 43.3% (for stage IV), respectively.
  • The analysis of survival rates revealed a significant difference between combined therapy and radiotherapy.
  • Conservation laryngectomy improves the quality of patient's life, and combined therapy is the best choice for hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Larynx / physiopathology. Larynx / surgery. Male. Middle Aged. Quality of Life. Reconstructive Surgical Procedures. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743643.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Koiwai K, Shikama N, Sasaki S, Shinoda A, Kadoya M: Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers. Jpn J Clin Oncol; 2009 Jul;39(7):413-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy from December 1998 to March 2006 were reviewed retrospectively.
  • The locations of the primary lesion were as follows: larynx in 18 patients, oropharynx in 11, nasopharynx in 7, hypopharynx in 7 and others in 4.
  • Clinical stages were as follows: Stage II in 20 and Stages III-IV in 27.
  • The median cumulative dose of cisplatin was 100 mg/m(2) (range, 80-300) and median radiation dose was 70 Gy (range, 50-70).
  • In univariate analysis, clinical stage (III-IV) (P = 0.017), primary site (oro-hypopharynx) (P = 0.041) and radiation portal size (>11 cm) (P < 0.001) were found to be associated with severe dysphagia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383615.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Corvò R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol; 2007 Oct;85(1):156-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based radiation oncology in head and neck squamous cell carcinoma.
  • BACKGROUND AND PURPOSE: Historically, radiation therapy (RT) has been an available treatment option for patients with early resectable head and neck squamous cell carcinoma (HNSCC) and the sole therapy for those with unresectable or inoperable disease.
  • Recently, four noteworthy strategies have emerged for the improvement of therapeutic outcome in the curative treatment of HNSCC: they include the development of altered fractionation radiotherapy, integration of chemotherapy with radiotherapy, incorporation of intensity-modulated radiotherapy and the introduction of targeted biological therapy.
  • These strategies are briefly reviewed in an effort to help interpret evidence-based data and to facilitate clinical-decision making in a clinical context.
  • MATERIALS AND METHODS: For patients with early stage HNSCC no level 1 study exists in which radiation therapy is compared with conservative surgery for the evaluation of local control or survival.
  • For patients with locally advanced HNSCC the recommendations to address the questions about better treatment in resectable and unresectable tumors are based on more than 100 randomized Phase III trials included in six meta-analyses on chemo-radiotherapy and/or altered fractionation.
  • RESULTS: External radiotherapy and/or brachytherapy are crucial treatment options in patients with early stage HNSCC.
  • For patients with locally advanced HNSCC, where outcome with conventional radiotherapy is poor, meta-analyses and collective data showed that loco-regional control may be improved at high level of evidence by altered fractionation radiotherapy, chemo-radiotherapy with concomitant approach or association of selected hypoxic cell radiosensitizer with radiotherapy.
  • Chemo-radiotherapy programs can achieve an improved larynx-function preservation program without the risk of overall survival reduction, for patients with larynx or hypopharynx tumors who are candidates to radical surgery followed by radiotherapy.
  • Despite improved results, a higher severe toxicity has been largely evidenced with concomitant chemo-radiotherapy by reducing the gain in the therapeutic index with new treatment strategies.
  • CONCLUSIONS: Stepwise improvements in HNSCC non-surgical therapy have shown favorable impact on loco-regional control and overall survival.
  • However, despite hundreds of clinical trials in patients with advanced disease, there is no absolute consensus about patient selection for altered fractionation regimens, type of chemo-radiotherapy association, radiation or chemotherapy dose schedule.
  • Nevertheless, many well-conducted clinical studies have expanded therapy options besides standard radiotherapy and have contributed to defining the evolving standard of care for patients with HNSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Evidence-Based Medicine. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Dose Fractionation. Humans. Nimorazole / therapeutic use. Radiotherapy, Conformal


18. Kubota A, Furukawa M, Fujita Y, Yagi H: [Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy]. Nihon Jibiinkoka Gakkai Kaiho; 2010 Mar;113(3):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
  • We evaluated clinical factors associated with concurrent chemoradiotherapy (CRT) toxicity and efficacy in resectable locoregionally advanced squamous cell carcinoma of the head and neck.
  • Subject were 115 subjects with stage III or IV carcinoma undergooing 58 to 70 Gy of irradiation (median total dose: 66 Gy) concurrently with 2 cycles of chemotherapy of 5FU at 1000 mg/m2, 120-hour continuous infusion and cisplatin at 60 mg/m2.
  • No significant difference in planned therapy completion was seen between 87% in N0 and 82% in N1 to 2.
  • OS differed significantly between 86% in stage III and 57% in IV, 78% in T0 to 2 and 62% in T3 to 4, 83% in N0 to 1 and 53% in N2, 77% in adjuvant chemotherapy (nedaplatin plus UFT) and 50% in no adjuvant chemotherapy, and 33% in the tongue and 77% in the oropharynx.
  • PFS significantly differed between 72% in T0 to 2 and 49% in T3 to 4, 77% in CR and 53% in PR, and 22% in the tongue and 58% in the hypopharynx, 66% in the oropharynx, and 53% in the larynx.
  • Multivariable analysis showed strongly independent risk factors associated with OS and PFS to be advanced T and N stage, no adjuvant chemotherapy, and the tongue as the site.
  • CRT was effective in treating resectable locoregionally advanced squamous cell carcinoma of the head and neck.
  • It is possible that adjuvant chemotherapy will improve CRT OS and PFS.
  • Other additional treatment will be needed, however, to improve OS and PFS in cases having a dismal diagnosis such as tongue cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged


19. Fallai C, Bolner A, Signor M, Gava A, Franchin G, Ponticelli P, Taino R, Rossi F, Ardizzoia A, Oggionni M, Crispino S, Olmi P: Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori; 2006 Jan-Feb;92(1):41-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx.
  • AIMS AND BACKGROUND: To compare conventional fractionation (CF) radiation therapy (RT), arm A, versus a split-course accelerated hyperfractionated schedule (S-AHF), arm B, versus CFRT plus concomitant chemotherapy (CT), arm C, in terms of five-year survival and toxicity for squamous cell tumors of the oropharynx.
  • METHODS AND STUDY DESIGN: Between January 1993 and June 1998, 192 previously untreated patients with stage III and IV oropharyngeal carcinoma (excluding T1N1 and T2N1) were enrolled in a multicenter randomized phase III trial (ORO 93-01).
  • In arms A and C, 66 to 70 Gy in 33 to 35 fractions was administered five days a week for six and a half to seven weeks.
  • In arm B, the dose delivered was 64 to 67.2 Gy in two fractions of 1.6 Gy every day, five days a week, with a planned two-week split at 38.4 Gy.
  • In arm C the CT regimen consisted of three cycles of carboplatin and 5-fluorouracil (CBDCA 75 mg/m2 on days 1 to 4 and 5-FU 1000 mg/m2 i.v. on days 1 to 4 every 28 days).
  • Distant metastases were fairly balanced in the three arms (A: 14; B: 9; C: 11), with a tendency towards more frequent isolated distant metastasis development in arm C (8 of 11 [72%] versus 7 of 23 [30%] in arms A+B).
  • The 13 second tumors were equally distributed and were mainly correlated with tobacco and alcohol consumption (five lung, two esophagus, two oral cavity, one larynx, one pancreas, one hepatocarcinoma, one myeloma).
  • Arm C showed slightly more G3+ late side effects involving subcutaneous tissues and mucosa, although significant late sequelae were relatively uncommon and the mucosal side effects were mostly transient.
  • The occurrence of persistent G3 xerostomia was comparable in the three treatment arms.
  • CONCLUSIONS: The results obtained with the combination of CT and RT compared with RT alone did not reach statistical significance, but combined treatment almost doubled the five-year overall survival, relapse-free survival and locoregional control rate.
  • Patients with advanced squamous cell carcinomas of the oropharynx who are medically suitable for the combined approach should be treated with a combination of radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Risk Factors. Salvage Therapy. Survival Analysis. Time Factors. Treatment Failure. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683383.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Rivera F, Vega-Villegas ME, López-Brea M, Isla D, Mayorga M, Galdós P, Rubio A, Del Valle A, García-Reija F, García-Montesinos B, Rodríguez-Iglesias J, Mayordomo J, Rama J, Saiz-Bustillo R, Sanz-Ortiz J: Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). Cancer Chemother Pharmacol; 2008 Jul;62(2):253-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
  • OBJECTIVES: We conducted a multicentric randomized phase II trial comparing 5-FU continuous infusion (PF) and cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy (IC) in locally advanced squamous cell head and neck cancer (LA-SCHNC).
  • RESULTS: A total of 206 patients (pts) were included (PF/UFTVP: 99/107): oral cavity: 8%/10%, oropharynx: 20%/25%, hypopharynx: 17%/14%, larynx: 54%/50%.
  • Stage (TNM, 2002): III: 41%/35%, IVA: 23%/27%, IVB: 35%/38%.
  • IC with UFTVP was associated with a favourable OS in the Cox analysis (actuarial 5 year OS: 49% vs. 34%; HR: 0.67, 95% CI: 0.47-0.95, P: 0.03).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease-Free Survival. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Tegafur / administration & dosage. Tegafur / adverse effects. Tegafur / therapeutic use. Uracil / administration & dosage. Uracil / adverse effects. Uracil / therapeutic use. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use


21. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM: Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1087-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
  • PURPOSE: Pretreatment anemia is an adverse prognostic variable in squamous cell head-and-neck cancer (HNC) patients treated with radiotherapy (RT) alone.
  • Tumor hypoxia is an adverse parameter for treatment with RT alone or with RT and concurrent chemotherapy (CCT).
  • This study was performed to evaluate whether pretreatment Hgb less than 13 g/dL was correlated with treatment outcome in patients with advanced HNC treated with a uniform regimen of RT/CCT.
  • METHODS AND MATERIALS: The study population consisted of patients with AJCC Stage III or IV, M0 HNC who were treated with 70 to 72.5 Gy accelerated hyperfractionated RT (1.25 Gy b.i.d.) and CCT consisting of 2 cycles of CDDP (12-20 mg/m(2)/d x 5 days) and continuous infusion 5-FU (600 mg/m(2)/d x 5 days) during Week 1 and Week 6.
  • These patients were enrolled on the experimental arm of a prospective randomized trial that compared this regimen to hyperfractionated irradiation alone from 1990 to 1996.
  • RT/CCT was delivered as standard therapy from 1996 to 2000.
  • Primary tumor sites included oropharynx (43%), hypopharynx/larynx (36%), oral cavity (9%), and nasopharynx (6%).
  • Seventy-eight percent of the patients with Hgb 13 g/dL or higher and 92% of the patients with Hgb less than 13 g/dL had a primary tumor stage of T3 or T4 (p = 0.01).
  • The therapeutic effect of anemia correction is being evaluated in prospective trials.
  • [MeSH-major] Anemia / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Failure

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752888.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Pradier O, Eberlein K, Weiss E, Jackel MC, Hess CF: Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer. Br J Radiol; 2001 Apr;74(880):368-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.
  • The feasibility and effectiveness of a combined chemoradiotherapy treatment modality for locally advanced head and neck cancer was tested in a phase II trial.
  • From March 1995 to June 1998, 35 patients with advanced squamous cell carcinoma of the head and neck were treated with a continuous intravenous infusion of 5-fluorouracil (600 mg m-2 24 h-1 for Days 1 to 5 (120 h)) and mitomycin-C (10 mg m-2 intravenously) on Day 5 during the first week of radiotherapy and on Day 36.
  • 31 patients had stage IV disease; 4 patients had stage III; and 1 patient had stage II.
  • The tumours involved were as follows: oral cavity (n = 11); oropharynx (n = 14); hypopharynx/larynx (n = 10).
  • Radiotherapy was delivered to a total dose of 70 Gy with conventional fractionation (2 Gy per fraction, five times a week).
  • Chemotherapy was well tolerated and all patients received the intended dose.
  • When a recurrence appeared, it was within the first year after treatment.
  • We observed a treatment interruption of maximum 1 week for six patients owing to mucositis.
  • The concomitant use of 5-fluorouracil, mitomycin-C and radiotherapy in locally advanced head and neck carcinoma is well tolerated in this group of patients.
  • This protocol showed good locoregional response with a very low toxicity profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Mitomycin / administration & dosage. Radiation Dosage. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387156.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Rogers LQ, Courneya KS, Robbins KT, Malone J, Seiz A, Koch L, Rao K, Nagarkar M: Physical activity and quality of life in head and neck cancer survivors. Support Care Cancer; 2006 Oct;14(10):1012-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Fifty-nine of 65 (91%) eligible head and neck cancer survivors recruited from an academic oncology clinic completed a self-administered survey including the modified Godin Leisure-Time Exercise Questionnaire and Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N), which includes physical, social, emotional and functional well-being (FWB) as well as additional concerns, and the FACT-General (FACT-G).
  • Cancer sites were primarily the oral cavity (24%), oropharynx (37%), or larynx (25%), with 20% being stage I, 7% stage II, 19% stage III, and 54% stage IV disease.
  • Chemotherapy and/or radiation were ongoing in 14% of the participants.
  • [MeSH-major] Carcinoma, Squamous Cell. Head and Neck Neoplasms. Motor Activity. Quality of Life. Survivors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 May;97(2):422-30 [15863140.001]
  • [Cites] Psychooncology. 2005 Nov;14(11):979-91 [15744764.001]
  • [Cites] Cancer Invest. 2004;22(1):30-50 [15069762.001]
  • [Cites] Cancer Nurs. 2001 Aug;24(4):255-63 [11502033.001]
  • [Cites] Psychooncology. 2002 Sep-Oct;11(5):389-400 [12228872.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Sep;31B(5):340-5 [8704653.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Rehabil Med. 2003 Jul;35(4):153-62 [12892240.001]
  • [Cites] Can J Appl Sport Sci. 1985 Sep;10(3):141-6 [4053261.001]
  • [Cites] Head Neck. 2005 Apr;27(4):281-8 [15668929.001]
  • [Cites] Am J Health Behav. 2003 May-Jun;27(3):246-56 [12751621.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Mar;120(3):427-36 [10064650.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1588-95 [16030088.001]
  • [Cites] Head Neck. 2004 Jun;26(6):518-30 [15162353.001]
  • [Cites] J Altern Complement Med. 1997 Fall;3(3):215-26 [9430325.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1660-8 [12721239.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):352-60 [10458254.001]
  • [Cites] Psychooncology. 2001 Sep-Oct;10(5):380-8 [11536416.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2001 Nov;23(11):954-61 [11754499.001]
  • [Cites] J Aging Health. 1993 May;5(2):179-93 [10125443.001]
  • [Cites] Psychooncology. 1999 May-Jun;8(3):191-206 [10390732.001]
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1035-56 [15801488.001]
  • (PMID = 16538497.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt ML, Srivastava K: Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume. Jpn J Clin Oncol; 2006 Sep;36(9):537-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the present study was to define the prognostic impact of nodal density (ND) and total tumor volume along with many other tumor, treatment and patient related variables using the late chemo-intensification treatment regimen with conventionally fractionated radiotherapy (70 Gy/7 weeks).
  • METHODS: A total of 74 patients with Stage III and IV biopsy proven squamous cell carcinoma of oropharynx, hypopharynx and larynx were treated with this regimen.
  • Chemotherapy consisted of continuous infusion of 5 FU at 350 mg/m(2)/day and cisplatin as 1 h infusion at 10 mg/m(2)/day on days 1-5 of week 6 and 7 of radiotherapy.
  • In the final multivariate Cox-regression model tumor stage, ND, primary site and nodal stage were independent variables predicting for LRFS.
  • Similarly AJCC group staging, ND and total treatment volume were found to have significant impact, independently over LRFS.
  • CONCLUSIONS: There is tremendous variation in terms of ND and total tumor volume within AJCC nodal staging and tumor staging, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905755.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


25. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging]. Strahlenther Onkol; 2007 Mar;183(3):138-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging.
  • PATIENTS AND METHODS: 600 patients (526 men, 76 women, median age 56 years) with ENT tumors (squamous cell carcinoma histology) were studied retrospectively.
  • The distribution of primary tumor site and stage (AJCC) was as follows: oropharynx: n = 161 (26.8%), hypopharynx: n = 187 (31.2%), oral cavity: n = 89 (14.8%), larynx: n = 118 (19.7%), cancer of unknown origin: n = 13 (2.2%), others: n = 32(5.3%), I: n = 24 (4%), II: n = 49 (8.2%), III: n = 89 (14.8%), IV: n = 438 (73%).
  • The following parameters were analyzed in association with distant metastases: tumor localization, T- and N-category, primary treatment, local tumor control, and second neoplasms.
  • RESULTS: 114/600 patients (19%) developed distant metastases, 29/600 (4.9%) at presentation, 50% within 9.3 months after diagnosis of the primary tumor.
  • Distant metastases were most frequent in stage IV (24.2%), carcinoma of the hypopharynx (25.7%), local recurrence (24.3%), and second neoplasm (31.7%) with the following distribution pattern: pulmonary 61/114 (53.5%), pleural 15/114 (13.1%), osseous 45/114 (39.5%), hepatic 14/114 (12.3%), cerebral 8/114 (7%), cutaneous 14/114 (12.3%).
  • CONCLUSION: With locally advanced ENT tumor stage IVa/b, carcinoma of the hypopharynx, local recurrence or second neoplasms, at least a pretherapeutic CT of the thorax should be performed because every seventh patient (88/600) developed metastases or second primary tumors within the thoracic space during the course of disease.
  • Regarding the side effects and costs of curative therapy, the definition of generally accepted guidelines for the systemic staging of locally advanced ENT tumors should be undertaken.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Otorhinolaryngologic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Bronchogenic / pathology. Carcinoma, Bronchogenic / secondary. Combined Modality Therapy. Disease Progression. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / pathology. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340072.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Yoon TM, Lee JK, Cho JS, Lim SC, Chung WK: Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer. J Otolaryngol Head Neck Surg; 2010 Apr;39(2):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer.
  • OBJECTIVES: The efficacy and toxicity of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy or radiotherapy only and their impact on laryngeal preservation and survival were studied in patients with supraglottic cancer.
  • METHODS: Forty-four patients with newly diagnosed supraglottic squamous cell carcinoma (stage II, III, IV) were treated with either two to three cycles of neoadjuvant chemotherapy with cisplatin 100 mg/m2 on day 1 and fluorouracil 800 to 1000 mg/m2 on days 1 to 5, followed by radiotherapy (NC + RT group, from March 1995 to December 1999; median 68.7 Gy, 1.8 to 2 Gy per fraction) or concurrent chemoradiotherapy (NC + CCRT group, from January 2000 to February 2003; radiotherapy concurrently with cisplatin 60 to 80 mg/m2 on day 1 and fluorouracil 600 to 800 mg/m2 on days 1 to 5).
  • Age, nodal stage, and tumour response after neoadjuvant chemotherapy were significant prognostic factors for OS and DSS (p < .05).
  • The 5-year disease-specific survival rates with larynx preservation were 42% in the NC + RT group and 73% in the NC + CCRT group (p = .028).
  • CONCLUSIONS: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with cisplatin and fluorouracil was effective as primary therapy for supraglottic cancer with laryngeal preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Supraglottic laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211100.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • PRACTICE GUIDELINE: These recommendations apply to adult patients with locally advanced (nonmetastatic stages iii-ivb) or recurrent or metastatic (stage IVC) HNSCC.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


28. Liu WS, Hsin CH, Chou YH, Liu JT, Wu MF, Tseng SW, Lee JK, Tseng HC, Wang TH, Su MC, Lee H: Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation. BMC Cancer; 2010;10:102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
  • BACKGROUND: The objective of this retrospective study is to investigate laryngeal preservation and long-term treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined with chemotherapy.
  • METHODS: Twenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent concurrent chemoradiotherapy.
  • The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six patients and weekly cisplatin for 19 patients.
  • RESULTS: The median follow-up time for survivors was 53.0 months (range 36-82 months).
  • The initial complete response rate was 85.2%, with a laryngeal preservation rate of 63.0%.
  • The 5-year functional laryngeal, local-regional control, disease-free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively.
  • The most common greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal stricture (18.5%, 5 of 27 patients), respectively.
  • CONCLUSIONS: After long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-regional control survival rates.
  • However, the late effect of laryngeal stricture remains a problem, particularly for high risk group patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Larynx / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Radiotherapy, Intensity-Modulated / adverse effects. Radiotherapy, Intensity-Modulated / methods. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):195-205 [10656393.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21 [16168834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):65-71 [10758306.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Cancer. 2001 Apr 20;96(2):126-31 [11291096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Laryngoscope. 1977 Aug;87(8):1288-303 [881922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):357-63 [6423584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Cancer J. 2006 Nov-Dec;12(6):494-500 [17207319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):36-41 [17709149.001]
  • [Cites] Auris Nasus Larynx. 2007 Dec;34(4):499-504 [17604583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85 [18164838.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] Acta Otolaryngol. 2009 Mar;129(3):311-7 [18607975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):146-53 [19553034.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Head Neck. 2005 Jan;27(1):15-21 [15515158.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 May;262(5):374-8 [15906056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30 [10701741.001]
  • (PMID = 20298550.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3087314
  •  go-up   go-down


29. Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I: Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer; 2001 Sep 1;93(5):725-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
  • Moreover, their influence on response to chemotherapy in cancer patients has been demonstrated.
  • To investigate the role of GST enzymes in carcinogenesis and in response to chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC), GSTP1, GSTM1 and GSTT1 were studied prospectively in a large series of HNSCC patients.
  • Correlations between GST alterations, p53 mutation status and clinical response to chemotherapy were investigated.
  • We showed that the risk of developing laryngeal cancer was increased by 2.6-fold [95% CI 1.6--6.1] in patients with the GSTM1 null genotype and by 2.8-fold [95% CI 0.9--8.1] in patients with the homozygous GSTP1 val105 genotype.
  • Two types of multivariate analysis were performed including parameters that have been shown to influence response to chemotherapy significantly in univariate analysis. p53 mutations and high tumor stage are independent factors of non-response to chemotherapy, whereas plasmatic GSTP1 levels and low tumor stage are independent factors of complete response.
  • Our data suggest that GST enzymes are associated with larynx cancer and that their use as predictive factors and treatment targets should be further explored.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Glutathione Transferase / blood. Head and Neck Neoplasms / enzymology. Isoenzymes / blood
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Gene Frequency. Genotype. Glutathione S-Transferase pi. Humans. Male. Middle Aged. Multivariate Analysis. Mutation. Neoadjuvant Therapy. Treatment Outcome. Tumor Suppressor Protein p53 / genetics


30. Allal AS, Taussky D, Mach N, Becker M, Bieri S, Dulguerov P: Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys; 2004 Apr 1;58(5):1431-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
  • The therapeutic ratio may be particularly favorable for 5-week regimens.
  • This study reports the 10-year experience of a single institution in the routine use of concomitant boost RT as standard radical treatment in all but the most favorable stage patients.
  • METHODS AND MATERIALS: Between February 1991 and June 2001, 296 patients (mean age, 59 years) were treated with concomitant boost RT either alone (67%) or combined with cisplatin-based chemotherapy (33%), with a median tumor dose of 69.9 Gy.
  • Tumors were located in the oropharynx in 52%, hypopharynx in 20%, larynx in 15%, nasopharynx in 7%, and oral cavity in 6%.
  • International Union Against Cancer Stage III-IV disease represented 77% of tumors.
  • Twenty patients (7%) had a treatment interruption (median, 5 days; range, 2-35 days).
  • Grade 3-4 Radiation Therapy Oncology Group acute toxicity was observed in 77% of patients, and nutritional support was required in 110 patients (37%).
  • In a multivariate analysis, only T and N stage was significantly associated with locoregional control and disease-free survival.
  • Concomitant chemotherapy administration is feasible provided that patients are carefully selected and supportive care is introduced in a timely fashion.
  • Considering the manageable toxicity and the satisfactory tumor control obtained, this regimen represents a good choice when considering implementation of an altered RT fractionation schedule as standard treatment for head-and-neck cancers.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050320.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Shimane T, Mori T, Ono T, Monden T, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
  • Palliative treatments are applied for older adult cases that are not indicated for either surgery or potential chemotherapy, as well as in cases with unresectable primary lesions, distant metastases, and serious complications among head and neck cancer cases.
  • There is no established treatment for such cases, and therefore treatment has to be selected on a case-by-case basis.
  • Two cases showing sustained QOL after long administration of S-1 are presented in this paper.
  • The first is an 84-year-old male patient with cancer of the hypopharynx (T3N2aM1, stage IVc).
  • The second is a 70- year-old male patient who had recurrent cancer of the larynx (T1N0M0, stage I) after primary treatment.
  • Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620804.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


32. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the head and neck.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Their ages ranged from 43 to 85 years, with a mean age of 62 years.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


33. Sumitsawan Y, Chaiyasate S, Chitapanarux I, Anansuthiwara M, Roongrotwattanasiri K, Vaseenon V, Tooncam H: Late complications of radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx; 2009 Apr;36(2):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late complications of radiotherapy for nasopharyngeal carcinoma.
  • The mean pre- and post-treatment body mass indexes (BMI) were 22.5+/-4 (15-35.6), and 19.8+/-3.2 (12.9-34.5; P<0.05).
  • Most of the patients (92%) had undifferentiated (50.5%) and poorly differentiated (41.5%) squamous cell carcinoma.
  • Eighty-eight percent of the patients were in Stage III and IV.
  • Chemotherapy was given to 145 patients (72.5%).
  • The mean post-radiation period in the added chemotherapy group was lower than the group treated with radiation alone (2.9+/-2.7 years vs. 5.4+/-4.4 years, P<.05).
  • Added chemotherapy increased the complication severity significantly for the skin (P<0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Quality of Life. Radiotherapy Dosage. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635325.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Jeremić B, Milicić B: Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy. Am J Clin Oncol; 2009 Apr;32(2):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
  • BACKGROUND: Identification of pretreatment prognostic factors influencing overall survival (OS) in locally advanced squamous cell carcinoma of the head and neck is an important issue in head and neck oncology.
  • METHODS: A total of 289 patients were treated with standard fraction or hyperfractionated radiation therapy with or without concurrent low-dose daily chemotherapy.
  • RESULTS: Gender (P = 0.43) and age (P = 0.26) did not influence OS whereas Karnofsky Performance Status (KPS) (P < 0.0001), T stage (P < 0.0001), and N stage (P < 0.0001) did.
  • Stage grouping was another factor that influenced OS (P < 0.001).
  • Patients with larynx and nasopharynx fared better than those with other primaries (P = 0.0153).
  • Finally, treatment significantly influenced OS.
  • Multivariate analysis showed that KPS, T and N stage, and treatment were independent prognosticators of OS.
  • CONCLUSIONS: KPS, T and N stage, and treatment are independent prognosticators of OS in patients with locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent low-dose daily chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Radiotherapy Dosage
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Randomized Controlled Trials as Topic. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307954.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS: Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1356-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment.
  • Candidate dysphagia-associated organs at risk were retrospectively contoured into original treatment plans.
  • Stage distribution was T1 (12 patients), T2 (10), T3 (4), T4 (2), and TX (3), and N2 (24), N3 (5), and NX (2).
  • Thirteen patients (42%) received concurrent chemotherapy during IMRT.
  • Mean dose to glottic larynx for the cohort was limited to 18 Gy (range, 6-39 Gy) by matching IMRT to conventional low-neck fields.
  • CONCLUSIONS: In the context of glottic laryngeal shielding, we describe candidate oral cavity and superior pharyngeal constrictor organs at risk and dose-volume constraints associated with preserved long-term swallowing function; these constraints are currently undergoing prospective validation.
  • Strict protection of the glottic larynx via beam-split IMRT techniques promises to make chronic aspiration an uncommon outcome.

  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6 [11448365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84 [12128118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1219-30 [14630255.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1000-5 [15978743.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1813-20 [17546592.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):568-74 [18793959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Head Neck. 2009 May;31(5):611-7 [19107949.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1034-41 [14648862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1072-82 [15001247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Dysphagia. 1996 Spring;11(2):93-8 [8721066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721-30 [8948358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92 [9588921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • (PMID = 20646872.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA132281; United States / NCI NIH HHS / CA / CA132281
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS575664; NLM/ PMC4034521
  •  go-up   go-down


36. Schwartz DL, Montgomery RB, Yueh B, Donahue M, Anzai Y, Canby R, Buelna R, Anderson L, Boyd C, Hutson J, Keegan K: Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer; 2005 Jun 15;103(12):2534-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
  • BACKGROUND: The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB-XRT) for locally advanced head and neck squamous cell carcinoma.
  • METHODS: Twenty patients with Stage III or IV (M0) disease of the oropharynx, supraglottic larynx, or hypopharynx were enrolled.
  • Patients with stable (SD) or responding disease subsequently received dose-escalated docetaxel (10-20 mg/m2 in sequential patient cohorts) and carboplatin AUC 1 weekly x 5 with CB-XRT (1.8 gray [Gy] every day x 15 days, followed by 1.8/1.5 Gy twice per day x 13 days).
  • RESULTS: All patients were evaluable, and 15 patients (5 patients with Stage III disease, 10 patients with Stage IV disease) completed all planned therapy.
  • Thirteen patients remain free of any disease event, with a median follow-up of 15 months (range, 3-29 months).
  • Early Phase II outcomes revealed promising activity in patients completing all treatment.
  • Initial induction response results suggested that further investigation of this regimen with more aggressive induction therapy is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15856475.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


37. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx].
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • The distribution of the patients according to UICC in 1997 was as follows: stage I 4, stage II 15, stage III 18, stage IV 30.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • CONCLUSIONS: Poorly differentiated carcinomas of the supraglottic larynx had characteristics of the advanced stage in terms of earlier lymph node metastasis and a relatively high rate of cervical and distant metastasis.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • For patients with T3 who need partial laryngectomy and patients with advanced N stage, the combination of surgery with radiotherapy was supposed to be a priority.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée qu'en est-il en pratique?
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • We found a higher frequency of laryngeal tumour in group 2 (31 vs 17; p =.03).
  • We observed more stage III and less stage IV in group 1.
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • The overall survival of the population (108 patients) was 81.5% at one year, 49.6% at 3 years and 35.3% at 5 years with a median survival of 3 years.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • If confirmed, cost effectiveness of such complication must be integrated in larynx preservation protocols.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Gil Z, Fliss DM: Contemporary management of head and neck cancers. Isr Med Assoc J; 2009 May;11(5):296-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNCs can originate in the skin or soft tissue, in the upper aerodigestive tracts (oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses, salivary glands), or in the thyroid.
  • In each of these sites, tumors vary not only by the primary site but also by pathophysiology, biological behavior, and sensitivity to radiotherapy or chemotherapy.
  • The main goals of therapy are ablation of the cancer while minimizing morbidity and preserving function and cosmesis.
  • Early-stage HNC (stage I and II) should be managed with a single modality, and advanced tumors (stage III and IV) with multimodality therapy.
  • Treatment should be directed to the primary tumor and the area of its lymphatic drainage--the neck lymph nodes.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Neck Dissection. Prognosis. Quality of Life. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637508.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Number-of-references] 29
  •  go-up   go-down


40. Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A: Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2007 Apr 1;67(5):1342-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
  • PURPOSE: To investigate the tumor control rates in locally advanced head-and-neck cancer using accelerated hypofractionated radiotherapy with chemotherapy.
  • METHODS AND MATERIALS: The data from patients with squamous cell cancer of the larynx, oropharynx, oral cavity, and hypopharynx (International Union Against Cancer Stage II-IV), who received accelerated hypofractionated radiotherapy with chemotherapy between January 1, 1998, and April 1, 2005, were retrospectively analyzed.
  • Two different chemotherapy schedules were used, carboplatin and methotrexate, both single agents administered on an outpatient basis.
  • When excluding patients with Stage II oral cavity, larynx, and hypopharynx tumors, 68 patients remained.
  • CONCLUSION: Accelerated hypofractionated radiotherapy and synchronous chemotherapy can achieve high tumor control rates while being resource sparing and should be the subject of prospective evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy / adverse effects. Dose Fractionation. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241752.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


41. Ghaffar S, Akhtar S, Ikram M, Imam SZ, Sepah YJ: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak; 2010 Mar;20(3):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma.
  • OBJECTIVE: To compare outcome of patients with advanced laryngeal hypopharyngeal squamous cell carcinoma treated surgically or with chemotherapy and/or radiotherapy.
  • METHODOLOGY: Medical records of already treated stage-III and IV squamous cell carcinoma of larynx/hypopharynx patients were reviewed.
  • Group-A comprised of patients treated with surgery +/- adjuvant therapy whereas non-surgically managed patients were labeled as group-B.
  • Kaplan Meier technique was used to estimate mean recurrence time with standard errors.
  • RESULTS: Sixty two percent of group-A and 49% patients of group-B were stage-III.
  • In group-A, 40% patients received postoperative adjuvant therapy while in group-B, 45% received concomitant chemoradiation.
  • Mean recurrence time was 1369+193 days.
  • In group-A, mean recurrence time was 2097+277 days.
  • The hazard ratio of recurrence in hypopharyngeal tumours was 1.5 times (95% CI 0.68, 3.30) as compared to tumours of larynx.
  • The hazard ratio of recurrence was 1.98 times (95% CI 0.99, 3.95) when both larynx and hypopharynx were involved as compared to when tumour was localized to larynx only.
  • No residual disease was noted at the completion of treatment in surgical group-A while 62% patients of the group-B had residual disease at the completion of treatment.
  • Larynx was retained in only 25% patients in group-B.
  • CONCLUSION: Statistically significant difference was noted in disease free outcome when stage-III and IV larynx hypopharynx cancer was managed surgically as compared to non-surgical management.
  • Chances of retaining larynx are only 25% when managed non-surgically.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392379.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


42. Lam P, Yuen AP, Ho CM, Ho WK, Wei WI: Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. Eur J Surg Oncol; 2001 Dec;27(8):750-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma.
  • AIMS: A prospective randomized study was conducted to evaluate the benefit of adjuvant levamisole/UFT (futraful and uracil) chemotherapy in head and neck squamous cell carcinoma.
  • METHODS: Sixty-five patients with stage III and IV squamous cell carcinomas of oral cavity, oropharynx, hypopharynx and larynx with no distant metastasis were randomized for the chemotherapy study.
  • Thirty-one patients were randomized for chemotherapy and two of them were subsequently excluded.
  • In this study, a total of 29 patients on levamisole/UFT therapy and 34 patients on the control group were analysed.
  • RESULTS: The rates of distant metastasis were 10% for chemotherapy group and 32% for control group (P=0.06).
  • The 5-year disease-free actuarial survival rates for patients with and without adjuvant chemotherapy were 57% and 39% respectively (P=0.207).
  • CONCLUSIONS: A trend of better distant control in head and neck cancer patients with post-operative adjuvant oral chemotherapy was observed.
  • It may be of value to conduct a large-scale multi-centre prospective randomized study to verify the efficacy of levamisole and UFT as post-operative adjuvant chemotherapy for the control of distant metastasis in high-risk population.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Levamisole / pharmacology. Uracil / pharmacology
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Radiotherapy, Adjuvant. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11735172.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 2880D3468G / Levamisole; 56HH86ZVCT / Uracil
  •  go-up   go-down


43. Nagahashi T, Fukuda S, Homma A, Yagi K, Furuta Y, Inuyama Y: Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma. Auris Nasus Larynx; 2001 May;28 Suppl:S95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma.
  • OBJECTIVE: To evaluate the efficacy and safety of concurrent carboplatin (CBDCA) and radiotherapy for laryngeal carcinoma. we investigated survival rates and laryngeal preservation rates in patients with this treatment modality and those with radiation therapy only.
  • METHODS: We underwent chemotherapy with CBDCA and conventional radiotherapy concurrently to 17 patients with untreated stage II (T2NOM0) supraglottic squamous cell carcinoma since November 1990.
  • CBDCA (100 mg/m2) was administered intravenously once a week concurrently with radiotherapy (2.5 Gy/fr, 4 times a week).
  • At the dose of 40 Gy, the results were evaluated, and some of the patients underwent planned surgery and others continued the radiotherapy up to 65 Gy.
  • Actual laryngeal preservation rate was 76.0%.
  • Compared with 14 cases of historical controls, which were treated by radiation therapy alone between 1988 and 1990, the cases with concurrent radiotherapy and chemotherapy had statistically significant advantage in overall successful laryngeal preservation rate (P < 0.05), whereas the two groups were not significantly different in the overall 5-year survival rate.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11683352.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Morales-Puebla JM, Toro-Rojas M, Segura-Saint-Gerons R, Fanego-Fernández J, López-Villarejo P: Basaloid squamous cell carcinoma: report of five cases. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e451-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: report of five cases.
  • OBJECTIVES: To document the clinical and histopathological characteristics of basaloid squamous cell carcinoma (BSCC).
  • CASES: retrospective review of five cases with the diagnosis of BSCC of the larynx.
  • Three patients presented with stage-IV disease and the other two with stage-I disease.
  • Surgery supplemented with radiation was used in three patients, partial surgery was used in another case and radiation and associated chemotherapy in the other one.
  • Central comedonecrosis within the cells nests, cell with nuclear palisading and high-grade dysplasia in overlaying mucosa are the main characteristics.
  • [MeSH-major] Carcinoma, Squamous Cell. Laryngeal Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038913.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


45. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol; 2010 Jun 20;28(18):2989-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
  • PATIENTS AND METHODS: Patients with previously untreated stage III or IV (excluding T1-2N1 and M1) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx were randomly assigned to receive definitive radiotherapy (70 Gy in 7 weeks) concurrently with either CIS (100 mg/m(2)) on day 1 of weeks 1, 4, and 7 or CIS (75 mg/m(2)) plus TPZ (290 mg/m(2)/d) on day 1 of weeks 1, 4, and 7 and TPZ alone (160 mg/m(2)/d) on days 1, 3, and 5 of weeks 2 and 3 (TPZ/CIS).
  • There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. International Agencies. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Quality of Life. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Triazines / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jun 20;28(18):2941-3 [20479396.001]
  • [ErratumIn] J Clin Oncol. 2014 May 1;32(13):1386
  • (PMID = 20479425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triazines; 1UD32YR59G / tirapazamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


46. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • Multivariate analysis of the overall population revealed that the only parameter that was significantly related to the probability of local control after RT was T stage.
  • CONCLUSIONS: The most important parameter that has an impact on local control after RT is T stage.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


47. Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R: The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol; 2004 Dec;31(6 Suppl 18):2-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
  • Concurrent chemotherapy and radiation has improved the outcome for patients presenting with locally advanced squamous cell carcinomas of the head and neck (SCCHN).
  • These improvements have come at a cost of increased treatment-related toxicities.
  • We previously reported the results of a phase II trial examining the role of concurrent carboplatin, paclitaxel, and daily radiotherapy (RT) in SCCHN.
  • From April 2002 to September 2004, 19 patients with stage III-IV SCCHN were enrolled on a prospective phase II trial.
  • Treatment consisted of daily RT delivered to 70.2 Gy (1.8 Gy/fx) with amifostine 500 mg IV (<1 hour before RT), and concurrent weekly carboplatin (100 mg/m2) and paclitaxel (40 mg/m2).
  • Tumor characteristics based on histology were: primary cancers of the oropharynx (55.6%); supraglottic larynx (16.7%); hypopharynx (16.7%); oral cavity (5.6%); and unknown primaries (5.6%).
  • Toxicities were measured weekly during treatment and at each follow-up visit.
  • Disease response to therapy was determined 2 months after completion of therapy.
  • Eighty-four percent completed the prescribed radiation treatment, and 84% of patients received more than six cycles of chemotherapy.
  • The median number of missed chemotherapy cycles was 1.5 (range, 0 to 5 cycles).
  • Grade 3 toxicities associated with therapy were: mucositis and dysphagia (40% of patients each), dehydration (27%), xerostomia (20%), and dermatitis (20%); 53% of patients experienced grade 3 leukopenia, while grade 3/4 neutropenia developed in 20%/13%.
  • Forty percent of patients completed RT without unscheduled treatment breaks secondary to treatment-related toxicity.
  • Median treatment-break time was 5 days (range, 0 to 20 days).
  • Weekly carboplatin and paclitaxel administered concurrently with definitive RT and daily amifostine is well tolerated, with over 85% of patients completing therapy with acceptable toxicity.
  • The addition of amifostine appears to decrease treatment-related toxicity without impacting efficacy.
  • [MeSH-major] Amifostine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / adverse effects. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mucous Membrane / drug effects. Paclitaxel / adverse effects
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726515.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


48. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, Kowalski LP: Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only patients with recurrent head and neck squamous cell carcinoma undergoing en bloc salvage resection were eligible for the study.
  • RESULTS: The tumor location was the lip in 6 patients, oral cavity in 55, oropharynx in 31, larynx in 24, and hypopharynx in 8.
  • Previous treatment was surgery alone in 20 patients, radiotherapy alone in 68, surgery and radiotherapy in 21, and radiotherapy and chemotherapy in 14.
  • An additional patient received chemotherapy alone before salvage surgery.
  • The clinical stage of the recurrent tumor was I or II in 23 patients and III or IV in 101 patients.
  • The major factor associated with the overall occurrence of postoperative complications was the clinical stage of the recurrent tumor (P =.02).
  • The occurrence of minor complications correlated with the previously treated site, with complications occurring more often in patients undergoing locoregional vs local treatment (P =.04).
  • Major complications were associated with the time between initial treatment and salvage surgery (P =.05).
  • The clinical stage of the recurrent tumor and the previous site treated were the 2 major factors associated with the occurrence of postoperative complications.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Morbidity. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676158.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Imauchi Y, Ito K, Takasago E, Nibu K, Sugasawa M, Ichimura K: Stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg; 2002 Jan;126(1):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx.
  • OBJECTIVE: Stomal recurrence after total laryngectomy is one of the most serious issues in the management of laryngeal carcinoma.
  • The management of stomal recurrence, including chemotherapy, radiotherapy, and surgery, has been reported as unsatisfactory.
  • STUDY DESIGN AND SETTING: From 1985 to 1995, 69 patients underwent total laryngectomy for the treatment of laryngeal cancer at the University of Tokyo Hospital.
  • RESULTS: Stomal recurrence developed in 6 of 69 patients who underwent total laryngectomy for laryngeal carcinoma.
  • CONCLUSION: Intensive follow-up should be performed for patients with glottic carcinoma who had preoperative tracheotomy, paratracheal lymph node metastasis, or both to detect stomal recurrence at an early stage.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Risk Factors. Salvage Therapy. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / epidemiology. Tracheal Neoplasms / secondary. Tracheotomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11821768.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Loré JM Jr, Kaufman S, Sundquist N, Chary KK: Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy. Ann Surg Oncol; 2003 Jul;10(6):645-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
  • BACKGROUND: A 5- to 20-year evaluation of preoperative chemotherapy uncompromised surgery and selective radiotherapy in stage III/IV head and neck squamous cell carcinoma.
  • Sites included the oral cavity, oropharynx, larynx, and hypopharynx.
  • The extent of surgery was carefully documented before chemotherapy-tattoo when feasible.
  • CONCLUSIONS: This study suggests treatment of advanced head and neck squamous cell carcinoma (resectable for cure) with preoperative chemotherapy (regimen B); resection of original tumor volume, regardless of response to chemotherapy; and selective (rather than routine) postoperative radiotherapy results in improved survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2003 Jul;10(6):593-5 [12839842.001]
  • (PMID = 12839849.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G: Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol; 2010 Nov;46(11):818-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
  • The aim of the present study was to identify a potentially effective new treatment regimen for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in disease progression after at least two previous chemotherapy regimens.
  • The regimen was administered to patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with surgery, radiotherapy or both and progressing after at least two chemotherapy regimens.
  • Twenty-four patients with histologically confirmed tumors of oral cavity, oropharynx, hypopharynx and larynx were enrolled.
  • All patients were stage IV and 91.6% had an ECOG PS 0-1.
  • After 3 cycles of treatment 23 patients (95.8%) were evaluable for response: 4 patients had partial response; 12 stable disease and 7 progressive disease.
  • The present study shows that the combination of Vinorelbine and Cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck patients is effective, feasible and has a good safety profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20920877.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 5V9KLZ54CY / Vinblastine; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


52. Hinerman RW, Morris CG, Amdur RJ, Lansford CD, Werning JW, Villaret DB, Mendenhall WM: Surgery and postoperative radiotherapy for squamous cell carcinoma of the larynx and pharynx. Am J Clin Oncol; 2006 Dec;29(6):613-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and postoperative radiotherapy for squamous cell carcinoma of the larynx and pharynx.
  • OBJECTIVE: To determine the rates of local-regional control, survival, and complications for patients treated with postoperative radiation for squamous carcinomas of the larynx, hypopharynx, and oropharynx.
  • METHODS: There were 295 patients with previously untreated squamous cell carcinomas of the larynx (n = 199), hypopharynx (n = 80), and oropharynx (n = 16) treated postoperatively with radiotherapy (RT).
  • RESULTS: Five-year local-regional control rates according to site and pathologic American Joint Committee on Cancer (AJCC) stage were: stage III larynx, 89% versus stage IVA larynx, 85% (P = 0.33); stage III oropharynx/hypopharynx, 76% versus stage IVA oropharynx/hypopharynx, 79% (P = 0.72).
  • Five-year absolute survival rates versus pathologic AJCC stage for the entire group were: stage III 59% and stage IVA 40% (P = 0.40).
  • Tumor control and survival will hopefully improve further with the addition of chemotherapy to postoperative radiation.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149000.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M: Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol; 2009 May;9(5):645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As biologic marker of cell death, both assays can be useful to evaluate prognosis and chemotherapy response in the patients with breast, lung, and endometrium cancer.
  • Median age was 51 years (range: 19-80) and squamous cell carcinoma of head and neck was major histopathologic subtype.
  • Primary tumors were localized in larynx, nasopharynx, hypopharynx and tongue.
  • There was no statistically significant correlation among age, stage and localization of tumor and serum M30 and M65 levels.
  • Significantly higher levels of serum M30 may have prognostic importance in this type of tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Head and Neck Neoplasms / blood. Keratin-18 / blood. Peptide Fragments / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / immunology. Drug Therapy. Enzyme-Linked Immunosorbent Assay. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reagent Kits, Diagnostic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249390.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Peptide Fragments; 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


54. Mesía R, Majem M, Barretina Ginesta MP, Galiana R, Mañós M, Guedea F, Montes A, Monner A, Pérez J, Cardenal F: Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy. Cancer Radiother; 2008 Mar;12(2):88-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy.
  • PURPOSE: The contribution of induction chemotherapy (CT) followed by hyperfractionated radiotherapy (hfRT) in unresectable squamous head and neck cancer has been evaluated in a single institution as an assistencial protocol.
  • All of them had stage IV-M0 disease: 67 T4, 88 N2-N3.
  • Tumor location: 62 oropharynx, 22 hypopharynx, eight oral cavity and seven larynx.
  • Tumor response at the end of treatment: 61 patients complete response, 17 partial response, two stable disease, 10 progressive disease and nine unevaluated.
  • With a median follow-up of 70 months the 5-year loco-regional control and overall survival was 30.3% (95% CI: 21.9-38.6) and 21.6% (95% CI: 13.4-29.8), respectively.
  • Chronic toxicity related to hfRT: six emergency tracheotomies due to laryngeal edema, five pneumonia and one mucous/soft-tissue necrosis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155633.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


55. Burian M: [Recommendation for guidelines in the treatment of squamous cell cancer of the upper aerodigestive tract]. Wien Med Wochenschr; 2008;158(9-10):283-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recommendation for guidelines in the treatment of squamous cell cancer of the upper aerodigestive tract].
  • [Transliterated title] Ein Vorschlag für Leitlinien der Behandlung von Plattenepithelkarzinomen des oberen Aerodigestivtraktes.
  • If we look at the historical development of the treatment of head and neck cancer, we can see that initially, decisions about therapy lay solely in the hands of the surgeons (Otorhinolaryngologists, oral and maxilla-facial surgeons) This was also true of the decision as to whether an operation was feasible or whether primary radio therapy was to be carried out.
  • At the end of the last century, after chemotherapy had become an integral part of curative therapy, inter-disciplinary conferences (tumour boards) were set up so that the surgeons could make joint decisions about therapy together with radio oncologists and medical oncologists.
  • In addition, the increasingly important role of chemotherapy in curative therapy in the last fifteen years has led to a marked increase in the number of clinical studies in head and neck cancer.
  • Inter-disciplinary treatment decisions can be based only on current scientific knowledge and are geared towards a standard treatment as recommended for an individual tumour stage.
  • It is precisely in the upper aerodigestive tract that there are various therapeutical procedures, due to the different site of primaries (oral cavity, oro-, hypoparynx and larynx) and the different grade of locoregional metastasis.
  • One possible way to assure a high degree of transparency of these various therapies and making them available to a high number of colleagues is the development guidelines [1].
  • Many medical associations and organisations in Austria are currently engaged in the formulation and definition of guidelines, in order to provide the highest possible quality of medical treatment and care for each individual patient.
  • By guidelines are meant recommendations for treatments which allow a certain amount of flexibility in the treatment and provide a medical consensus in line with current scientific knowledge.
  • The following proposal is designed to provide a basis for the formulation of guidelines for the treatment of head and neck cancer in Austria.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Otorhinolaryngologic Neoplasms / therapy. Practice Guidelines as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560956.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


56. Luna-Ortiz K, Villavicencio-Valencia V, Saucedo-Ramírez OJ, Rascón-Ortiz M: [Laryngeal cancer in patients younger than 40 years]. Cir Cir; 2006 Jul-Aug;74(4):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laryngeal cancer in patients younger than 40 years].
  • [Transliterated title] Cáncer de laringe en pacientes menores de 40 años.
  • BACKGROUND: We undertook this study to report demographic data of laryngeal cancer patients <40 years old and treatment results.
  • METHODS: In a retrolective study we reviewed the clinical records of 500 patients with laryngeal cancer in the period from 1989 to 2004 and included those patients<40 years of age.
  • Nine (60%) were men and six (40%) were women, with a 1.5:1 ratio.
  • Average time of evolution at the time of diagnosis was 14.4 months (range 0-36 and median of 12 months); 60% of the patients were smokers and 40% admitted to drinking alcohol; dysphonia was the main symptom found in 87% of the patients.
  • Initial treatment was surgery in four (27%) patients; radiotherapy in five (33%) patients receiving an average of 63.44 Gy; concomitant chemoradiotherapy in one patient (7%) using gemcitabine; four (27%) patients were treated with neoadjuvant chemotherapy followed by radiotherapy; and one patient did not receive treatment.
  • The average time in which the patients relapsed after the first treatment was 19.57 months (range 2-63) and four were classified as persistent.
  • Survival time was 32 months (range 2-106 and median 27 months).
  • CONCLUSIONS: Squamous cell carcinoma of the larynx is rare in patients<40 years old in our study.
  • Prognosis for these patients was determined by the initial clinical stage.
  • [MeSH-major] Laryngeal Neoplasms / therapy

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022892.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


57. Hatoum GF, Abitbol A, Elattar I, Lewin A, Troner M, Kronberg F, Raez LE, Weed D, Abdel-Wahab M: Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes. Head Neck; 2009 Jul;31(7):944-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionation (A-3 protocol) or accelerated fractionation (A-4 protocol) with chemotherapy.
  • RESULTS: Thirty-five evaluable A-3 protocol patients, 14 evaluable A-4 protocol patients, and 6 patients treated per A-4 protocol guidelines, but without amifostine as they refused the medication, were included in the analysis.
  • Pretreatment characteristics, such as sex, age, race, T classification, N classification, American Joint Committee on Cancer (AJCC) stage, were compared between the 2 groups of patients.
  • The only significant difference between the 2 groups was AJCC stage.
  • Type of altered fractionation scheme may not influence PEG dependence in patients treated with similar protocols.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Enteral Nutrition. Gastrostomy. Head and Neck Neoplasms / radiotherapy. Intubation, Gastrointestinal
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Endoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309724.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


58. Corvò R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, Pallestrini E, Merlano M, Vitale V, Rosso R: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer; 2001 Dec 1;92(11):2856-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.
  • BACKGROUND: The authors previously have found that in patients with locally advanced squamous cell carcinoma of the head and neck (SCC-HN), alternating chemoradiotherapy (ALT) was superior to low-total-dose conventional radiotherapy alone.
  • METHODS: During 6 years, 136 consecutive patients with previously untreated unfavorable Stage II or Stage III-IV (International Union Against Cancer) SCC of the oral cavity, pharynx, and larynx were enrolled.
  • They were randomly assigned to chemotherapy consisting of 4 cycles of intravenous cisplatin (20 mg/m(2) of body surface area per day for 5 consecutive days) and 5-fluorouracil (200 mg/m(2) per day for 5 consecutive days; weeks 1, 4, 7, and 10) alternated with three 2-week courses of radiotherapy (20 grays [Gy] per course, 2 Gy per day, 5 days per week; ALT, 70 patients) or to partly accelerated radiotherapy with final concomitant boost technique (75 Gy/40 fractions in 6 weeks; partly accelerated radiotherapy [PA-RT], 66 patients).
  • RESULTS: At the median follow-up of 60 months (range, 30-102 months), no statistical differences were observed in overall survival, progression free survival, or locoregional control between the 2 treatments.
  • Therefore, definitive conclusions could not be made.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Second Primary / etiology. Patient Compliance. Regression Analysis. Treatment Outcome


59. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):410-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
  • PURPOSE: To review the University of Iowa experience with intensity-modulated radiotherapy (IMRT) in the treatment of head-and-neck squamous cell carcinoma.
  • METHODS AND MATERIALS: From October 1999 to April 2004, 151 patients with head-and-neck squamous cell carcinoma were treated with IMRT for curative intent.
  • One patient was lost to follow-up 2 months after treatment and therefore excluded from analysis.
  • Of the remaining 150 patients, 99 were treated with definitive IMRT, and 51 received postoperative IMRT.
  • Sites included were nasopharynx, 5; oropharynx, 56; larynx, 33; oral cavity, 29; hypopharynx, 8; nasal cavity/paranasal sinus, 8; and unknown primary, 11.
  • None of the patients treated with postoperative IMRT received chemotherapy.
  • Of 99 patients who had definitive IMRT, 68 patients received concurrent cisplatin-based chemotherapy.
  • One patient received induction cisplatin-based chemotherapy, but no concurrent chemotherapy was given.
  • The prescribed doses to CTV1, CTV2, and CTV3 in the definitive cohort were 70-74 Gy, 60 Gy, and 54 Gy, respectively.
  • For high-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 64-66 Gy, 60 Gy, and 54 Gy, respectively.
  • For intermediate-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 60 Gy, 60 Gy, and 54 Gy.
  • The median time from treatment completion to local-regional recurrence was 4.7 months (range, 1.8 to 15.6 months).
  • Patients with oropharyngeal cancer did significantly better than patients with oral cavity and laryngeal cancer, with a 2-year local-regional control rate of 98%, compared with 78% for oral cavity cancer and 85% for laryngeal cancer (p = 0.005).
  • There was no significant difference in local-regional control for patients who received postoperative radiation or definitive radiation (p = 0.339) and for patients who had chemotherapy or not (p = 0.402).
  • Neither T stage nor N stage had a significant effect on local-regional control (p = 0.722 and 0.712, respectively).
  • More studies are necessary to further improve the outcomes of laryngeal cancer as well as oral cavity cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Iowa. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Failure. Universities

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Kohno N: The role of chemotherapy for advanced oro and hypopharyngeal cancer. Auris Nasus Larynx; 2004 Jun;31(2):113-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy for advanced oro and hypopharyngeal cancer.
  • Although important progress continuous to be made in the treatment of oro and hypopharyngeal cancer, the 5-year survival rate for all this disease has remained at less than 30% for the past 30 years.
  • In the early 1980s, chemotherapy was introduced with high expectation of reducing in the incidence of distant metastases and increasing the possibility of local control.
  • This article explores the use of chemotherapy in the treatment of advanced pharyngeal cancer.
  • Thus, the efficacy of chemotherapy are reviewed and treatment options for advanced pharyngeal cancer are made.
  • When advanced carcinoma is still localized, function-preserving surgery is performed.
  • In these cases, the possibility of instituting adjuvant chemotherapy with an active treatment regimen may be taken into account depending on the condition of the patient and the tumor.
  • Patients with surgically resectable tumors are given 1-2 cycles of induction chemotherapy.
  • Cases who respond to the induction chemotherapy are subsequently given concurrent chemoradiotherapy.
  • The cases who do not respond to the induction chemotherapy are treated with radical surgery.
  • Patients with unresectable carcinoma are given concurrent chemoradiotherapy because local treatment should be performed in such patients as early as possible.
  • In principle, concurrent regimens should be supplemented with adjuvant chemotherapy in all cases.
  • This is particularly required for those with advanced N-stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15121218.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


61. Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):461-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy.
  • PURPOSE: To report the treatment outcomes of definitive radiotherapy (RT) for early-stage squamous cell carcinoma (SCCA) of the glottic larynx.
  • METHODS AND MATERIALS: We retrospectively reviewed the medical records of 585 patients with T1N0 to T2N0 invasive SCCA of the glottic larynx treated between 1964 and 2006 with RT alone.
  • None of these patients received chemotherapy or had elective nodal RT.
  • The probabilities of local control (LC), ultimate LC, ultimate LC with larynx preservation, neck control, cause-specific survival (CSS), and overall survival (OS) were calculated by the Kaplan-Meier product-limit method.
  • Multivariate analysis revealed that overall treatment time greater than 41 days (p = 0.001) and poorly differentiated histology (p = 0.016) adversely affected LC.
  • Five-year rates of ultimate LC with laryngeal preservation were: T1A, 95%; T1B, 94%, T2A, 81%; and T2B, 74%.
  • One patient died of a radiation-induced carotid artery angiosarcoma.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Glottis / pathology. Glottis / surgery. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Radiation Injuries / complications. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153124.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Hehr T, Classen J, Welz S, Ganswindt U, Scheithauer H, Koitschev A, Bamberg M, Budach W: Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study. Radiother Oncol; 2006 Jul;80(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To determine the outcome, acute and late toxicity in locally advanced head and neck cancer stage IVA with mitomycin-C (MMC), cisplatin (DDP) chemotherapy and hyperfractionated accelerated radiation therapy (C-HART).
  • PATIENTS AND METHODS: Thirty-five patients, with squamous cell cancer of the oral cavity (20%), oropharynx (37%), hypopharynx (26%) and larynx (17%), received 30 Gy (2 Gy every day) followed by 1.4 Gy bid to a total of 70.6 Gy concurrently with MMC 10mg/m(2) (day 1 plus 36) and DDP 6 mg/m(2) given Mondays through Fridays during weeks 1-3.
  • Mucositis is a frequent, severe toxicity in patients treated with C-HART for head and neck cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / pharmacology. Combined Modality Therapy / methods. Dose Fractionation. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Mitomycin / pharmacology
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Female. Humans. Male. Middle Aged. Prospective Studies. Radiation-Sensitizing Agents / pharmacology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875750.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Radiation-Sensitizing Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


63. Mantz CA, Vokes EE, Kies MS, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ: Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol; 2001 Mar;12(3):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer.
  • PURPOSE: To determine overall survival, progression-free survival, rate of voice preservation, and patterns of failure in locoregionally advanced laryngeal cancer treated with induction chemotherapy with or without surgery followed by concomitant chemoradiation.
  • BACKGROUND: Locoregionally advanced laryngeal cancer has been conventionally treated with either surgery and adjuvant radiotherapy or radiotherapy alone, and clinical and functional outcomes have been poor.
  • Chemoradiotherapy has been demonstrated to improve functional outcome and disease control over conventional treatment in recent randomized head and neck trials.
  • Induction treatment consisted of three cycles of cisplatin, 5-fluorouracil (5-FU), leucovorin, and interferon-alpha 2b (PFL-IFN) followed by surgery for residual disease.
  • Surgical intent was to spare the larynx when possible.
  • RESULTS: A subset of thirty-two laryngeal cancer patients with predominantly stage IV disease comprises the study group for this report.
  • Clinical CR was observed in 59% of patients following induction therapy.
  • Only two total laryngectomies were performed during the course of treatment and follow-up.
  • Treatment-related toxicity accounted for two deaths.
  • CONCLUSIONS: The addition of concomitant chemoradiotherapy to induction chemotherapy for locoregionally advanced laryngeal cancer appears to increase locoregional control and survival rates.

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332146.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Pradier O, Christiansen H, Schmidberger H, Martin A, Jäckel MC, Steiner W, Ambrosch P, Kahler E, Hess CF: Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1368-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck.
  • PURPOSE: To evaluate the efficacy of an adjuvant radiotherapy after transoral laser microsurgery for advanced squamous cell carcinoma of the head and neck and to show that a less invasive surgery with organ preservation in combination with radiotherapy is an alternative to a radical treatment.
  • PATIENTS AND METHODS: Between 1987 and 2000, 208 patients with advanced squamous cell carcinoma of the head and neck were treated with postoperative radiotherapy after surgical CO2 laser resection.
  • Primary sites included oral cavity, 38; oropharynx, 88; larynx, 36; hypopharynx, 46.
  • Disease stages were as follows: Stage III, 40 patients; Stage IV, 168 patients.
  • Before 1994, the treatment consisted of a split-course radiotherapy with carboplatinum (Treatment A).
  • After 1994, the patients received a conventional radiotherapy (Treatment B).
  • Patients treated with a hemoglobin level greater or equal to 13.5 g/dL before radiotherapy had a 5-year DSS of 55% as compared with 39% for patients treated with a hemoglobin level greater than 13.5 g/dL (p = 0.0054).
  • Treatment B has clearly been superior to Treatment A.
  • A further improvement of our treatment regimen might be expected by the combination of adjuvant radiotherapy with concomitant platinum-based chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery. Laser Therapy / methods. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hemoglobin A / analysis. Humans. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Mouth Neoplasms / radiotherapy. Mouth Neoplasms / surgery. Multivariate Analysis. Neoplasm Recurrence, Local. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):955; author reply 955-6 [16751078.001]
  • (PMID = 16169679.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9034-51-9 / Hemoglobin A
  •  go-up   go-down


65. Airoldi M, Cattel L, Cortesina G, Giordano C, Pedani F, Recalenda V, Danova M, Gabriele AM, Tagini V, Porta C, Bumma C: Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol; 2004 Apr;27(2):155-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study.
  • Concomitant chemoradiotherapy is the most effective treatment of unresectable head and neck cancer.
  • Docetaxel and carboplatin are two active drugs that potentiate radiotherapy.
  • Thirty patients (median age = 56 years; median Eastern Cooperative Oncology Group performance status = 1) received radiotherapy (70 Gy, 2 Gy/d, 5 d/wk) concurrent with carboplatin AUC 0.3 to 0.5 on day 1-5, weeks 1, 3, 5, 7, and docetaxel 15 to 25 mg/m2 on day 4 of weeks 2, 4, and 6.
  • Site of unresectable squamous cell carcinoma was as follows: oropharynx, 41%; hypopharynx, 27%; oral cavity, 16%; and larynx, 16%.
  • Stage was III in 13% and IV in 87%.
  • Median radiotherapy dose was 69 Gy, and 175 out of 210 courses (83%) were administered.
  • At the end of the treatment, we had 20 complete responses (CR) (67%), 9 partial responses (30%), and 1 no change (3%).
  • Carboplatin, docetaxel, and concomitant conventional radiotherapy is a feasible and effective treatment of unresectable head and neck cancer.
  • The concurrent administration of two drugs does not alter pharmacokinetic drug behavior compared with single-agent data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Area Under Curve. Carboplatin / administration & dosage. Carboplatin / pharmacokinetics. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Survival Analysis. Taxoids / administration & dosage. Taxoids / pharmacokinetics. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15057155.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


66. Portaluri M, Fucilli FI, Castagna R, Bambace S, Pili G, Tramacere F, Russo D, Francavilla MC: Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation. Int J Radiat Oncol Biol Phys; 2006 Nov 15;66(4):1036-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.
  • PURPOSE: To evaluate the dosimetric parameters of three-dimensional conformal radiotherapy (3D-CRT) in locally advanced head-and-neck tumors (Stage II and above) and the effects on xerostomia.
  • METHODS AND MATERIALS: A total of 49 patients with histologically proven squamous cell cancer of the head and neck were consecutively treated with 3D-CRT using a one-point setup technique; 17 had larynx cancer, 12 oropharynx, 12 oral cavity, and 6 nasopharynx cancer; 2 had other sites of cancer.
  • Of the 49 patients, 41 received postoperative RT and 8 definitive treatment.
  • Also, 13 were treated with cisplatin-based chemotherapy before and during RT; in 6 cases, 5-fluorouracil was added.
  • The follow-up time was 484-567 days (median, 530 days).
  • The mean dose to the primary planning target volume was 49.54 +/- 4.82 Gy (51.53 +/- 5.47 Gy for larynx cases).
  • The average dose to the contralateral parotid gland was approximately 38 Gy (30 Gy for larynx cases).
  • The maximal dose to the spinal cord was 46 Gy.
  • A Grade 0 Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer xerostomia score corresponded to a mean dose of 30 Gy to one parotid gland.
  • A lower xerostomia score with a lower mean parotid dose and longer follow-up seemed to give rise to a sort of functional recovery phenomenon.
  • With a mean dose of approximately 30 Gy to the contralateral parotid, we observed no or mild xerostomia.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiometry / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Burden. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Relative Biological Effectiveness. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750321.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB: Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol; 2010 Feb;21(2):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.
  • BACKGROUND: Panitumumab has the potential to improve the therapeutic ratio of concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN).
  • PATIENTS AND METHODS: This phase I dose-finding study investigated escalating doses of paclitaxel (Taxol) given concurrently with panitumumab, carboplatin and intensity-modulated radiotherapy (IMRT) for stage III-IVB SCCHN.
  • Untreated patients with oral cavity, oropharynx, larynx, hypopharynx or unknown primaries were eligible.
  • Additional eligibility criteria included measurable disease, good performance status and no contraindication to therapy.
  • CONCLUSIONS: Panitumumab, carboplatin, paclitaxel and IMRT are well tolerated and appear highly active in the treatment of SCCHN.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892746.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / panitumumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


68. Nishimura G, Tsukuda M, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Kawakami M, Watanabe M, Niho T, Abo H, Yamomoto S: Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation. Anticancer Res; 2009 Feb;29(2):661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation.
  • BACKGROUND: Although the survival rate of early-stage laryngeal squamous cell carcinoma (SCC) patients treated by radiotherapy (RT) is sufficient, the larynx preservation rate is unsatisfactory.
  • To improve the larynx preservation rate, such patients have been treated by RT with chemotherapeutic agents.
  • There were no significant differences in the response and survival rates between the treatment methods both in T1 and T2 cases.
  • The 5-year larynx preservation survival rate was improved significantly by CCRT in T2 cases (66.7% vs. 93.3%; p < 0.01).
  • CONCLUSION: CCRT for early-stage laryngeal SCC patients was efficacious to improve the larynx preservation survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tegafur / administration & dosage. Tegafur / adverse effects. Thyroid Gland / drug effects. Thyroid Gland / radiation effects. Uracil / administration & dosage. Uracil / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331217.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin; 1-UFT protocol
  •  go-up   go-down


69. Galiana R, Boladeras A, Mesía R, Gómez J, de Juan A, Mañós M, Nogués J, Navarro V, Guedea F: Twice-a-day radiotherapy for head and neck cancer: the Catalan Institute of Oncology experience. Radiother Oncol; 2002 Jul;64(1):19-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From 1992 to 1999, 318 patients with squamous head and neck tumours treated by hyperfraction RT were analysed according to their sub-localisation and stage.
  • Fractions used were 1.2 Gy twice-a-day with a curative intent on all patients, to a total mean dose of 79.14 Gy.
  • Treatment protocols by localisation were: larynx: 55 patients with T2N0 and T1-2N1 tumours treated with only RT and 27 patients with T3N0-1 in complete remission after three cycles of induction chemotherapy (ICT); hypopharynx: 29 patients with T2-4N0-2b resectable tumors in response to three cycles of ICT; oropharynx: 48 patients with T2-3N0-1 and T1N1 tumours treated with only RT; 34 patients with nasopharynx tumours treated with RT and three cycles of ICT if T4 or >N1; finally, 125 patients with non-surgical tumours of any localisation treated with four cycles of induction CT and RT.
  • RESULTS: LARYNX: Actuarial local control (LC), disease-free survival (DFS) and overall survival (OS) at 5 years were 78, 73 and 48%, respectively, in T2 tumours and 75, 72 and 60% in stage III disease.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Otorhinolaryngologic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ireland Ltd.
  • (PMID = 12208570.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


70. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB: T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. Am J Clin Oncol; 2007 Apr;30(2):181-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience.
  • PURPOSE: The purpose of this study was to report the outcomes after external-beam radiotherapy (RT) for selected T3 and T4 vocal cord squamous cell carcinomas.
  • METHODS AND MATERIALS: One hundred nine patients with previously untreated T3 and T4 squamous cell carcinomas of the glottic larynx were treated with curative intent in this Institutional Review Board-approved outcome study using continuous-course RT alone (106 patients) or followed by a planned neck dissection (3 patients) between September 1966 and June 2002.
  • Patients selected for such treatment had relatively low-volume, unilateral disease.
  • Patients were staged according to the recommendations of the American Joint Committee on Cancer (AJCC) as follows: T3N0, 68 patients (62%); T3N1, 14 patients (13%); T3N2B, 5 patients (5%); T4N0, 17 patients (16%); T4N1, 4 patients (4%); and T4N2B, 1 patient.
  • RESULTS: The 5-year outcomes after treatment were: local control for stage T3 and T4, 78% and 81%; locoregional control for AJCC stage III and IVa, 62% and 78%; distant metastasis-free survival for AJCC stage III and IVa, 97% and 100%; cause-specific survival for AJCC stage III and IVa, 84% and 87%; and overall survival for AJCC stage III and IVa, 52% and 67%, respectively.
  • Local control and ultimate cure probabilities will hopefully improve further with the addition of concomitant chemotherapy to RT for larger tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy. Vocal Cords

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414468.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope; 2009 Aug;119(8):1518-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 variant isoforms in head and neck squamous cell carcinoma progression.
  • The objective of this study was to investigate the role of the CD44 v3, v6, and v10 variant isoforms in head and neck squamous cell carcinoma (HNSCC) tumor progression behaviors.
  • STUDY DESIGN: Laboratory study involving cell cultures and clinical tissue specimens.
  • METHODS: Analysis of the expression of standard CD44s and the CD44 variant isoforms v3, v6, and v10 was carried out in the HNSCC cell line, HSC-3.
  • Immunohistochemical analysis was performed on clinical tissue specimens obtained from a series of 82 HNSCC patients.
  • The expression of standard CD44s and the CD44 v3, v6, and v10 variants in primary tumor specimens (n = 82) and metastatic cervical lymph nodes (n = 24) were analyzed with respect to various clinicopathologic variables.
  • Compared with primary tumors, a greater proportion of metastatic lymph nodes demonstrated strong expression of CD44 v3 (lymph node 14/24 vs. primary tumor 38/82), CD44 v6 (lymph node 18/24 vs. primary tumor 26/82), and CD44 v10 (lymph node 14/24 vs. primary tumor 16/82), while expression of standard CD44 was not significantly different in metastatic lymph nodes and primary tumors (lymph node 10/24 vs. primary tumor 60/82).
  • Expression of CD44 variant isoforms were associated with advanced T stage (v3 and v6), regional (v3) and distant (v10) metastasis, perineural invasion (v6), and radiation failure (v10).
  • CD44 v6 and CD44 v10 were also significantly associated with shorter disease-free survival.
  • Furthermore, expression of certain CD44 variants may be important molecular markers for HNSCC progression and should be investigated as potential therapeutic targets for therapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 Mar;85(4):514-8 [10691836.001]
  • [Cites] Semin Cancer Biol. 2008 Aug;18(4):251-9 [18450475.001]
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):410-5 [10804289.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1088-95 [11014576.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1217-23 [11031408.001]
  • [Cites] Tumour Biol. 2001 Jan-Feb;22(1):45-53 [11054026.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):115-20 [11223837.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32 [11283501.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5275-83 [11431370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):628-35 [11764382.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4067-72 [11751503.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48679-92 [11606575.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] J Lab Clin Med. 2002 Jan;139(1):59-65 [11873246.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2059-64 [12209509.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):745-7 [12213700.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25285-8 [12738783.001]
  • [Cites] Auris Nasus Larynx. 2004 Mar;31(1):35-41 [15041052.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):102-18 [15051494.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26991-7007 [15090545.001]
  • [Cites] Exp Mol Pathol. 2004 Aug;77(1):18-25 [15215046.001]
  • [Cites] Front Biosci. 1998 Jul 1;3:d637-49 [9634539.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):443-55 [8426113.001]
  • [Cites] J Cell Physiol. 1995 Jan;162(1):127-33 [7529235.001]
  • [Cites] J Pathol. 1996 May;179(1):66-73 [8691348.001]
  • [Cites] J Cell Physiol. 1997 May;171(2):152-60 [9130462.001]
  • [Cites] J Cell Physiol. 1998 Jul;176(1):206-15 [9618160.001]
  • [Cites] Front Biosci. 1999 Jan 1;4:A1-8 [9872731.001]
  • [Cites] Cell Motil Cytoskeleton. 1999;43(4):269-87 [10423269.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):837-45 [10446451.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):19-24 [16415424.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14026-40 [16565089.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1356-65 [16557236.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):771-8 [16847188.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1163-8 [16855392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):281-8 [17372087.001]
  • [Cites] Head Neck. 2007 Jun;29(6):550-8 [17252589.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] J Cell Physiol. 2000 May;183(2):182-95 [10737894.001]
  • (PMID = 19507218.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA066163-14; United States / NCI NIH HHS / CA / R01 CA078633-10; United States / NIAMS NIH HHS / AR / P01 AR039448-190007; United States / NCI NIH HHS / CA / CA078633-10; United States / NCI NIH HHS / CA / R01 CA066163-14; United States / NCI NIH HHS / CA / R01 CA66163; United States / NIAMS NIH HHS / AR / P01 AR039448; United States / NCI NIH HHS / CA / R01 CA078633; United States / NIAMS NIH HHS / AR / AR039448-190007; United States / NIAMS NIH HHS / AR / P01 AR39448; United States / NCI NIH HHS / CA / R01 CA066163
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS113866; NLM/ PMC2718060
  •  go-up   go-down


72. El-Deiry M, Funk GF, Nalwa S, Karnell LH, Smith RB, Buatti JM, Hoffman HT, Clamon GH, Graham SM, Trask DK, Dornfeld KJ, Yao M: Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg; 2005 Oct;131(10):879-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer.
  • OBJECTIVE: To compare the long-term, health-related quality-of-life outcomes in patients with advanced head and neck cancer (HNC) treated with surgery and postoperative radiation therapy (SRT) or concurrent chemotherapy and radiation therapy (CRT).
  • DESIGN: Matched-pair study comparing patients with advanced HNC treated with SRT or CRT at least 12 months after treatment.
  • PATIENTS: Patients with stage III or IV squamous cell carcinoma of the oropharynx, hypopharynx, and larynx who underwent SRT or received CRT.
  • RESULTS: The matching process resulted in 27 patients in each treatment group.
  • [MeSH-minor] Combined Modality Therapy. Female. Health Status Indicators. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Speech, Alaryngeal

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230590.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA106908-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


73. Morimoto M, Takemura H, Yui T, Suzuki T, Sanbe T, Suzaki H: [Efficacy of concomitant therapy with S-1, CDGP, and radiation for laryngeal cancer]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1903-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of concomitant therapy with S-1, CDGP, and radiation for laryngeal cancer].
  • OBJECTIVE: Several clinical trials examining treatment strategies for advanced laryngeal cancer have demonstrated that concurrent chemoradiotherapy is the most effective treatment for improving the patient response to radiotherapy and laryngeal preservation.
  • We evaluated a new regimen of S-1/CDGP(Nedaplatin) with radiotherapy (RT), and established that it represented an effective new treatment option that allowed for the preservation of the larynx.
  • METHODS: A total of 16 patients with stage II to IV laryngeal cancer(excluding T4 stage)who had been treated at our institution from 2001 to 2007 were recruited for the present study.
  • All patients had histologically-confirmed squamous cell carcinomas.
  • RESULTS: The administration of S-1/CDGP/RT led to a complete response (CCR) in all patients with stage II or IV disease, with preservation of the larynx in all of these cases.
  • For patients with stage III disease, 6 (85%) experienced CR, and 1 patient (15%) had a partial response.
  • The laryngeal preservation rate for these patients was 85%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948253.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


74. Vivek RS, Baludavid M, Mohanram R, Chitra, Amanullah, Vijayalakshmi, Bala, Kalaiyarasi, Saravanan: Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas. J Cancer Res Ther; 2006 Jul-Sep;2(3):90-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
  • PURPOSE: To investigate the feasibility of combining concomitant boost-accelerated radiation regimen (ACB) with full-dose mono-chemotherapy using cisplatin and to assess its local response and acute toxicity patterns in patients with advanced loco-regional head and neck squamous cell carcinoma (HNSCC).
  • MATERIALS AND METHODS: Between July 2004 and August 2005, a pilot study involving 27 patients with stage III to IVB (AJCC-6th) HNSCC of the oropharynx, hypopharynx and larynx who met the eligibility criteria was undertaken.
  • The radiation dose was 72 Gy in 42 fractions over 6 weeks, delivered in one daily fraction of 1.8 Gy during the first 3.5 weeks and two fractions per day, 1.8 Gy and 1.5 Gy boost-separated by > 6 h interval, during the last 2.5 weeks. cisplatin, 100 mg/m2, was given in intravenous (i.v.) infusion on day 1 and day 22.
  • RESULTS: Out of 27 patients, 24 patients received both radiation and chemotherapy as per protocol and were available for analysis.
  • CONCLUSION: This data shows that it is feasible to combine ACB and full-dose mono-chemotherapy using cisplatin with manageable, although substantial, toxicity.
  • The compliance to therapy was high and the loco-regional response achieved compared favorably with ACB alone or other concurrent chemoradiation regimens using standard or altered fractionation regimens tested by the Institute.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Patient Compliance. Pilot Projects


75. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst; 2008 Feb 20;100(4):261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
  • BACKGROUND: The improved prognosis for patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC observed in retrospective analyses remains to be confirmed in a prospective clinical trial.
  • METHODS: We prospectively evaluated the association of tumor HPV status with therapeutic response and survival among 96 patients with stage III or IV HNSCC of the oropharynx or larynx who participated in an Eastern Cooperative Oncology Group (ECOG) phase II trial and who received two cycles of induction chemotherapy with intravenous paclitaxel and carboplatin followed by concomitant weekly intravenous paclitaxel and standard fractionation radiation therapy.
  • The presence or absence of HPV oncogenic types in tumors was determined by multiplex polymerase chain reaction (PCR) and in situ hybridization.
  • The relative hazard of mortality and progression for HPV-positive vs HPV-negative patients after adjustment for age, ECOG performance status, stage, and other covariables was estimated by use of a multivariable Cox proportional hazards model.
  • RESULTS: Genomic DNA of oncogenic HPV types 16, 33, or 35 was located within tumor cell nuclei of 40% (95% confidence interval [CI] = 30% to 50%) of patients with HNSCC of the oropharynx or larynx by in situ hybridization and PCR.
  • Compared with patients with HPV-negative tumors, patients with HPV-positive tumors had higher response rates after induction chemotherapy (82% vs 55%, difference = 27%, 95% CI = 9.3% to 44.7%, P = .01) and after chemoradiation treatment (84% vs 57%, difference = 27%, 95% CI = 9.7% to 44.3%, P = .007).
  • After a median follow-up of 39.1 months, patients with HPV-positive tumors had improved overall survival (2-year overall survival = 95% [95% CI = 87% to 100%] vs 62% [95% CI = 49% to 74%], difference = 33%, 95% CI = 18.6% to 47.4%, P = .005, log-rank test) and, after adjustment for age, tumor stage, and ECOG performance status, lower risks of progression (hazard ratio [HR] = 0.27, 95% CI = 0.10 to 0.75), and death from any cause (HR = 0.36, 95% CI = 0.15 to 0.85) than those with HPV-negative tumors.
  • CONCLUSION: For patients with HNSCC of the oropharynx, tumor HPV status is strongly associated with therapeutic response and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / virology. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / virology. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Dose Fractionation. Drug Administration Schedule. Female. Humans. In Situ Hybridization. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Paclitaxel / administration & dosage. Polymerase Chain Reaction. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome


76. Erisen LM, Coskun H, Ozuysal S, Basut O, Onart S, Hizalan I, Tezel I: Basaloid squamous cell carcinoma of the larynx: a report of four new cases. Laryngoscope; 2004 Jul;114(7):1179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the larynx: a report of four new cases.
  • OBJECTIVES: This study is designed to report the clinical and pathologic features and outcome of cases of basaloid squamous cell carcinoma (BSCC) of the larynx treated in our clinic.
  • METHODS: Four cases of BSCC of the larynx were treated in our department.
  • RESULTS: All patients were male (mean 57), with supraglottic or transglottic larynx tumors.
  • Two patients presented with stage-II disease and the other 2 with stage-IV disease.
  • Initial diagnosis was invasive squamous cell carcinoma in 3 patients and BSCC in one patient.
  • Two patients who had stage-II disease underwent partial laryngectomy and bilateral neck dissections; total laryngectomy and bilateral neck dissections were performed in stage-IV patients.
  • Three patients received adjuvant postoperative radiotherapy, and 2 of them also received additional chemotherapy.
  • Patients with stage-IV disease were found to have 4 and 27 metastatic lymph nodes on histopathologic examination and died because of distant metastases at 11 and 14 months, respectively.
  • Patients with stage-II disease did not have cervical metastasis on histopathologic examination and were alive and free of disease at 52 and 72 months respectively.
  • CONCLUSION: In contrast with the literature reporting the tendency of more aggressive clinical behavior of the BSCC, we can say that BSCC has a behavior similar to conventional squamous cell carcinoma based on our 4 cases.
  • [MeSH-major] Carcinoma, Basosquamous / therapy. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Immunohistochemistry. Male. Middle Aged. Neck Dissection. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15235344.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wolf GT, Bradford CR, Urba S, Smith A, Eisbruch A, Chepeha DB, Teknos TN, Worden F, Dawson L, Terrell JE, Hogikyan ND: Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer. Laryngoscope; 2002 Aug;112(8 Pt 1):1351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer.
  • OBJECTIVE: To determine whether pretreatment lymphocyte subpopulations correlate with tumor response to induction chemotherapy as part of an organ preservation treatment approach in patients with advanced laryngeal cancer.
  • STUDY DESIGN: A prospective clinical trial in patients with advanced laryngeal cancer was undertaken to determine whether the frequency of late salvage laryngectomy and overall survival could be improved using one cycle of neoadjuvant chemotherapy to select patients for organ preservation.
  • Pretreatment peripheral blood lymphocyte subpopulations for CD3, CD4, CD8, NK, and B cells were correlated with tumor response to induction chemotherapy, larynx preservation, and survival, to determine whether immune parameters could be useful in patient selection.
  • Studied were 53 patients with stage III (42%) or IV (57%) larynx cancer.
  • Sixty-eight percent had greater than 50% tumor response after one cycle of induction chemotherapy and then received concurrent chemoradiation and two cycles of adjuvant chemotherapy.
  • Only 4 cases were late salvage resections (13-35 mo after treatment).
  • Fourteen cases were planned surgery after initial chemotherapy.
  • Of the lymphocyte subpopulations measured, CD8 levels were significantly lower in stage IV patients and tended to be lower in patients with successful organ preservation.
  • However, no significant differences in lymphocyte subpopulations were found among responders and nonresponders to chemotherapy.
  • CONCLUSIONS: One cycle of neoadjuvant chemotherapy was effective in selecting patients for organ preservation.
  • The regimen of definitive concurrent and adjuvant chemotherapy was associated with an unexpectedly high 2-year survival rate.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / immunology
  • [MeSH-minor] Chemotherapy, Adjuvant. Follow-Up Studies. Humans. Laryngectomy. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172244.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-46592-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


78. Kim JG, Sohn SK, Kim DH, Baek JH, Jeon SB, Chae YS, Lee KB, Park JS, Sohn JH, Kim JC, Park IK: Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer; 2005 Nov 14;93(10):1117-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
  • We aimed to evaluate the efficacy and safety of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  • In total, 37 patients with stage III or IV SCCHN were enrolled on the study.
  • The chemotherapy consisted of two cycles of intravenous cisplatin of 80 mg m(-2) on day 1 and oral capecitabine 825 mg m(-2) twice daily from day 1 to day 14 at 3-week intervals.
  • The radiotherapy (1.8-2.0 Gy 1 fraction day(-1) to a total dose of 70-70.2 Gy) was delivered to the primary tumour site and neck.
  • The primary tumour sites were as follows: oral cavity (n=6), oropharynx (n=11), hypopharynx (n=8), larynx (n=3), nasopharynx (n=6), and paranasal sinus (n=3).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Capecitabine. Disease Progression. Drug Therapy, Combination. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1472-81 [12237916.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1893-8 [12453857.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1115-20 [12853355.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3098-104 [12915600.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1578-86 [14504061.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):348-52 [14735175.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2648-53 [7989940.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):485-93 [10080589.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1350-7 [15684318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1961-9 [11283128.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2948-53 [10537364.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • (PMID = 16251869.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361495
  •  go-up   go-down


79. Worden FP, Moyer J, Lee JS, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Hogikyan N, Lassig AA, Emerick K, Mukherji S, Hadjiski L, Tsien CI, Miller TH, Wallace NE, Mason HL, Bradford CR, Wolf GT: Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope; 2009 Aug;119(8):1510-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
  • OBJECTIVES/HYPOTHESIS: High rates of overall survival (OS) and laryngeal preservation were achieved in two sequential phase II clinical trials in patients with stage III/IV laryngeal squamous cell carcinoma (SCC).
  • Patients were treated with chemoradiation after a >50% primary tumor response to one cycle of neoadjuvant chemotherapy (IC).
  • METHODS: Records from 36 patients with T4 SCC of the larynx with cartilage invasion alone (n = 16) or cartilage invasion and extralaryngeal spread (n = 20) were retrospectively reviewed.
  • Those achieving >50% response at the primary tumor received chemoradiation (70 Gy; 35 fractions with concurrent cisplatin-100 mg/m(2) [carboplatin (AUC 6)] every 21 days for 3 cycles), followed by adjuvant P+5FU for complete histologic responders (CHR).
  • Of these, 27 received definitive chemoradiation, 23 (85%) obtained CHR, with 58% laryngeal preservation rate.
  • Following chemoradiation, 8/11 (73%) patients with an intact larynx had >75% understandable speech, 6/36 (17%) were g-tube dependent and 6/36 (17%) were tracheostomy dependent.
  • CONCLUSIONS: Our results suggest that chemo-selection is a feasible organ preservation alternative to total laryngectomy for patients with T4 laryngeal SCC with cartilage invasion.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1478-85 [11720432.001]
  • [Cites] Head Neck. 2002 May;24(5):456-67 [12001076.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):467-72 [6486314.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):564-9 [2364368.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):559-68 [9635702.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):830-5 [16564646.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):655-61 [16785412.001]
  • [Cites] Curr Opin Oncol. 2007 May;19(3):188-94 [17414635.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 19504552.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-05; United States / NCI NIH HHS / CA / P50 CA97248; United States / NIDCD NIH HHS / DC / P30 DC 05188; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NIDCD NIH HHS / DC / DC005188-07; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NCI NIH HHS / CA / CA097248-05; United States / NIDCD NIH HHS / DC / P30 DC005188-07; United States / NIDCR NIH HHS / DE / DE013346-05; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS126278; NLM/ PMC2739984
  •  go-up   go-down


80. Homma A, Shirato H, Furuta Y, Nishioka T, Oridate N, Tsuchiya K, Nagahashi T, Aoyama H, Inuyama Y, Fukuda S: Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J; 2004 Sep-Oct;10(5):326-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.
  • PURPOSE: This randomized, phase II study aimed to compare concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin as a treatment for squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: One hundred nineteen patients with moderate- to advanced-stage disease were eligible for the study.
  • Fifty-three patients had stage II disease, 28 had stage III, and the remaining 38 had stage IV disease.
  • Primary tumor sites included the larynx (N = 63), oropharynx (N = 30), hypopharynx (N = 23), and oral cavity (N = 3).
  • The radiotherapy dose of 65 Gy was given in 26 fractions over 45 days, dependent on a good tumor response at 40 Gy.
  • RESULTS: The median follow-up time was 63 months.
  • The 5-year overall survival rate did not significantly differ between treatments: 71.4% for carboplatin and 66.0% for cisplatin.
  • DISCUSSION: These findings suggest that weekly carboplatin treatment is preferable to daily low-dose cisplatin.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15530262.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N: [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study]. Acta Otorrinolaringol Esp; 2003 Dec;54(10):697-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
  • [Transliterated title] Quimioterapia de inducción con vinorelbine, cisplatino y UFT en carcinomas avanzados faringo-laríngeos: resultados de un estudio fase II.
  • OBJECTIVE: To evaluate the results of an induction chemotherapy protocol with Vinorelbine, UFT and Cisplatin (UFTVP).
  • METHODS: 93 patients with laryngo-pharyngeal squamous cell carcinoma in stage III or IV were prospectively entered into a protocol to receive four cycles of UFTVP.
  • Responders followed definitive radiation therapy.
  • RESULTS: Following chemotherapy nodal response (complete in 28% and partial in 33%) was less than that the primary site (complete in 60% and partial in 30%), p = 0.002.
  • With a median follow-up of 62 months, the Kaplan-Meier 5-year survival was 45%.
  • Successful larynx preservation was achieved in 50% of patients with laryngeal cancer and in 29% of patients with hypopharyngeal cancer.
  • CONCLUSIONS: UFTVP is an active regime of chemotherapy in advanced squamous cell carcinoma of the pharynx and larynx.
  • Results differ according to the localization, having significantly better rates of survival and organ preservation in the laryngeal cancers that in those of the pharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngectomy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Prospective Studies. Remission Induction. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15164709.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; 1-UFT protocol
  •  go-up   go-down


82. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 95 cases of squamous cell carcinoma of the external and middle ear.
  • OBJECTIVE: To analyze the clinical characteristics, 5-year survival, and prognostic factors of squamous cell carcinoma (SCC) of the external and middle ear.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • RESULTS: This disease seems to appear in the elderly with a peak age of 50-69 years.
  • Males appear to be more predisposed than females with an odd ratio of 1.7.
  • SCC located in the external ear could be detected in an earlier stage than that in the middle ear.
  • The overall 5-year survival was 66.8% in total, and decreased significantly with stage.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • Stage, completeness of operation with tumor free margin, recurrence, and metastasis have significant influence on survival.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • Tumor stage adds more influence on survival than its location.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Ear Neoplasms / epidemiology. Ear, External. Ear, Middle

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


83. Scheuermann K, Delank KW: [Perforation of the esophagus with a mediastinal abscess]. HNO; 2005 Jan;53(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perforation of the esophagus with a mediastinal abscess].
  • [Transliterated title] Osophagusperforation mit Mediastinalabszess. Eine Spätkomplikation der chirurgischen Stimmrehabilitation nach Laryngektomie.
  • CASE REPORT: The 69 year old patient underwent laryngectomy, selective bilateral neck dissection and the implantation of a Provox voice prosthesis because of a glottic squamous cell carcinoma (pT(4), pN(0), M(0)).
  • During adjuvant radiochemotherapy, the patient developed distinctive cervical edema which led to a tilting of the Provox prosthesis.
  • Due to a perforation of the posterior esophageal wall, the patient developed a pronounced mediastinal abscess which was relieved through a transcervical mediastinotomy.
  • Antibiotic therapy led to a partial remission of the symptoms.
  • CONCLUSION: Severe complications may not only occur during the early phase of surgical voice rehabilitation, but also at a much later stage, after completion of the healing process.
  • In particular, when the tissue is injured during the course of radiotherapy, this type of complication should be taken into consideration.
  • [MeSH-major] Abscess / etiology. Abscess / surgery. Esophageal Perforation / etiology. Larynx, Artificial / adverse effects. Mediastinal Diseases / etiology. Mediastinal Diseases / surgery. Prosthesis-Related Infections / etiology. Prosthesis-Related Infections / surgery
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Bacterial Infections / drug therapy. Bacterial Infections / etiology. Bacterial Infections / surgery. Humans. Male. Prosthesis Failure. Treatment Outcome. Voice Disorders / rehabilitation. Voice Disorders / surgery

  • MedlinePlus Health Information. consumer health - Abscess.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Otorhinolaryngol. 2001 May;258(4):173-6 [11407448.001]
  • [Cites] Laryngorhinootologie. 2002 Dec;81(12):890-3 [12486628.001]
  • [Cites] Laryngoscope. 1989 May;99(5):489-91 [2709936.001]
  • [Cites] Laryngorhinootologie. 1994 Feb;73(2):84-7 [8161415.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Sep;116(9):1074-6 [2116810.001]
  • [Cites] HNO. 1995 Mar;43(3):197-201 [7759304.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):762-3 [2115667.001]
  • [Cites] Laryngoscope. 1997 Apr;107(4):527-30 [9111385.001]
  • [Cites] Otolaryngol Head Neck Surg. 1985 Dec;93(6):809-11 [3937107.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Nov;126(11):1320-8 [11074828.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1988 Sep-Oct;97(5 Pt 1):537-41 [3178106.001]
  • [Cites] HNO. 1994 Feb;42(2):99-103 [8163402.001]
  • [Cites] Laryngoscope. 1985 Nov;95(11):1360-2 [4058216.001]
  • [Cites] HNO. 2000 Jul;48(7):508-16 [10955228.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1202-7 [2233085.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Aug;120(8):840-5 [8049046.001]
  • [Cites] Am J Otolaryngol. 1990 Mar-Apr;11(2):85-9 [2344000.001]
  • [Cites] HNO. 1990 Nov;38(11):417-20 [2289900.001]
  • [Cites] Laryngoscope. 1987 May;97(5):562-7 [3573901.001]
  • (PMID = 15064925.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


84. Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H: Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol; 2006 Jun;120(6):478-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx.
  • This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx.
  • Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66-72 Gy.
  • The three-year overall survival rate with larynx preservation was 100 per cent.
  • Concurrent chemoradiotherapy with carboplatin and UFT for stage two SCC of the glottic larynx was safe and effective in improving local control with larynx preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563197.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin
  •  go-up   go-down


85. de la Vega FA, García RV, Domínguez D, Iturre EV, López EM, Alonso SM, Romero P, Sola JM: Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas: final results of a single institutional program. Am J Clin Oncol; 2003 Dec;26(6):550-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas: final results of a single institutional program.
  • SUMMARY: ABSTRACT The purpose of this study was to achieve locoregional control of locally advanced laryngeal carcinoma, survival, and organ preservation using split hyperfractionated accelerated radiation therapy and cisplatin concomitantly.
  • This study was a phase II trial of chemoradiotherapy with split hyperfractionated accelerated radiation therapy, 1.6 Gy per fraction given twice per day to a total dose of 64 to 67.2 Gy for a total of 6 weeks with a 2-week gap, and cisplatin 20 mg/m2, days 1 to 5, in continuous perfusion, concomitantly.
  • Seventy-three patients were treated (stage IV, 64%).
  • Of the 73 patients, 32 (44%) have continued with their larynx free of disease.
  • Split hyperfractionated accelerated radiation therapy and concomitant cisplatin has been demonstrated to be an active treatment for locally advanced laryngeal carcinomas, but more active combinations of chemotherapy and radiotherapy, without increase of toxicity, are necessary to increase the rate of locoregional control, organ preservation, and survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14663370.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


86. Sas-Korczynska B, Korzeniowski S, Skolyszewski J: Cancer of the larynx in females. Cancer Radiother; 2003 Dec;7(6):380-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the larynx in females.
  • PURPOSE: The aim of this paper is to present results of analysis of 102 females with laryngeal cancer.
  • MATERIALS AND METHODS: Between 1974 and 1995, 102 female patients with cancer of larynx were treated at Radiotherapy Department of Oncology Centre in Kraków.
  • The treatment method depended on stage of disease.
  • Primary radical irradiation was performed in 66 patients, 29 patients received postoperative radiotherapy after surgery (total or partial laryngectomy), seven patients received induction chemotherapy followed by laryngectomy with postoperative radiotherapy or radical irradiation.
  • The median dose applied with radiotherapy was 60 Gy, and dose per fraction was 2 Gy.
  • Only tumour stage and nodal involvement were found to be significant factor for all three endpoints.
  • CONCLUSIONS: The tumour stage and nodal involvement were found to be significant prognostic factors in analysed group of female treated with laryngeal cancer.
  • [MeSH-major] Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Follow-Up Studies. Humans. Laryngectomy. Larynx / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Postoperative Care. Prognosis. Radiotherapy Dosage. Sex Factors. Smoking / adverse effects. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14725911.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


87. Tai SK, Yang MH, Wang LW, Tsai TL, Chu PY, Wang YF, Huang JL, Chang SY: Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer. Jpn J Clin Oncol; 2008 Aug;38(8):521-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
  • OBJECTIVE: Laryngeal preservation is a challenge for the treatment of advanced hypopharyngeal cancer.
  • The objective of this study is to evaluate the results of chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer at a single institute and the impact of treatment factors on prognosis.
  • METHODS: The study population consisted of 42 consecutive patients with resectable stage III-IV hypopharyngeal cancer.
  • Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) was performed in 32 (76.2%) patients, whereas primary CCRT was done in the other 10 (23.8%).
  • Patients were grouped according to the dose intensity of chemotherapy and total dose of radiotherapy (RT).
  • CT- and RT-optimum both correlated significantly with better disease-free survival (DFS) (P < 0.001 and = 0.003), overall survival (OS) (P < 0.001 and = 0.004) and laryngeal preservation survival (LPS) (P = 0.01 and 0.04).
  • CONCLUSIONS: Achievement of optimum treatment dose remains challenging in chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
  • The criteria for selecting patients who will respond to and complete the treatment remain key issues for future investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Larynx / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. X-Rays


88. Yokoyama J: [Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer]. Gan To Kagaku Ryoho; 2002 Feb;29(2):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer].
  • Patients with head and neck squamous cell cancers (HNSC) of stage III and IV have a poor outcome, often losing important functions such as swallowing and speech despite combined surgery and radiotherapy.
  • Two-thirds of such patients die of local recurrence and disseminated metastasis in spite of salvage therapy.
  • Conventional adjuvant chemotherapy is often difficult for HNSC patients, since many of them suffer from associated chronic oral, respiratory and gastrointestinal diseases due to tobacco and alcohol in addition to having poor nutritional and oral hygienic conditions.
  • Ninety-seven patients with advanced head and neck cancers were treated by superselective intra-arterial chemotherapy using CDDP and sodium thiosulfate (STS) from 1995 to 2000.
  • The complete and partial response rates were 72% and 25%, respectively, with 100% preservation of the larynx and 90% preservation of the eyeball in all involved cases.
  • We could suppress mucositis of normal tissue and chemotoxicities leading to conditions such as renal and hematological dysfunction.
  • Though our method currently has disadvantages such as the risk of cerebral infarction, the fact that chemotherapy must always be done under fluoroscopy, and the occurrence of distant metastasis, there are good prospects for the future and we are now working toward solving the present problems.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Antidotes / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial / methods. Male. Middle Aged. Prospective Studies. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SODIUM THIOSULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865620.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antidotes; 0 / Antineoplastic Agents; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 24
  •  go-up   go-down


89. Kubota A, Furukawa M, Komatsu M, Hanamura H, Sugiyama M: [Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Mar 20;109(3):149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
  • To evaluate the efficacy of adjuvant chemotherapy after concurrent chemoradiotherapy, 41 previously untreated patients with locally advanced and resectable head and neck squamous cancer were enrolled in a study to compare adjuvant chemotherapy (Nedaplatin/UFT) after concurrent chemoradiotherapy (CDDP/5-FU) and concurrent chemoradiation alone.
  • Nine of the patients had stage III tumors and 32 had stage IV tumors.
  • The primary tumor site was the hypopharynx in 14 patients, the larynx in 12 patients, the oral cavity in 9 patients, and the oropharynx in 6 patients.
  • Treatment consisted of 6 courses of Nedaplatin (80 mg/m2) repeated at 4-week intervals and one year of the oral administration of UFTE (400 mg/day) after concurrent chemoradiotherapy at an outpatient clinic.
  • The median overall survival time was 30.1 months (5.5-50.1 months) for the adjuvant chemotherapy group and 21.7 months (4.0-48.8 months) for the control group.
  • The progression-free survival period was 22.8 months (5.6-33.9 months) for the adjuvant chemotherapy group and 26.5 months (5.6-33.9 months) for the control group.
  • The two-year overall survival rate was 73.3% for the adjuvant chemotherapy group and 55.7% for the control group.
  • A significant difference was observed in the two-year progression-free survival rates: 66.9% for the adjuvant chemotherapy group and 27.8% for the control group (p = 0.03290).
  • Among the patients with a partial response to concurrent chemoradiotherapy, in particular, a significant difference in the two-year progression-free survival rates was seen : 59.3% for the adjuvant chemotherapy group and 15.3% for the control group (p = 0.01102).
  • The rate of loco-regional failure was 29.6% for the adjuvant chemotherapy group and 64.3% for the control group (p = 0.0716).
  • The rate of organ preservation was 66.7% for the adjuvant chemotherapy group and 35.7% for the control group (p = 0.1183).
  • This adjuvant chemotherapy regimen might improve the loco-regional control rates after concurrent chemoradiotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615429.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Qureshi SS, Chaturvedi P, Pai PS, Chaukar DA, Deshpande MS, Pathak KA, D'cruz AK: A prospective study of pharyngocutaneous fistulas following total laryngectomy. J Cancer Res Ther; 2005 Jan-Mar;1(1):51-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It leads to increased morbidity, delay in adjuvant treatment, prolonged hospitalization and an increase in treatment costs.
  • We undertook a prospective study to critically analyze PC fistula and its association with various tumors, patient and treatment related factors.
  • This was a prospective study that included 143 patients who underwent laryngeal surgery for squamous cell carcinoma of the larynx and pyriform sinus.
  • Use of pectoralis major myocutaneous flap to reconstruct the neopharynx, primary disease in pyriform and extensive soft tissue infiltration were significantly associated with PC fistula.
  • Prior treatment (radiotherapy and chemotherapy), type of closure (T closure, Y closure and vertical closure), Layers of closure (full thickness interrupted, submucosal interrupted, submucosal continuous) type of suture material (silk, vicryl ), age, sex, stage, preoperative tracheostomy, cut margin status, pre/postoperative hemoglobin and experience of surgeons did not relate significantly.

  • MedlinePlus Health Information. consumer health - Fistulas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998627.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


91. Leu YS, Hsiao HT, Chang YC, Yang CC, Lee JC, Chen YJ, Chang YF: Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report. Acta Otolaryngol; 2005 Jun;125(6):642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report.
  • CONCLUSION: The new technique of ileocolic free flap reconstruction provides a better quality of life in terms of swallowing and speech for patients who have undergone laryngopharyngectomy with concomitant chemotherapy and radiotherapy (CCRT).
  • MATERIAL AND METHODS: This was a follow-up study of 12 patients with advanced (stages III, IVA and IVB) laryngeal and hypopharyngeal cancer who underwent major surgery, CCRT (with one exception) and ileocolic free flap reconstruction.
  • RESULTS: All patients were able to tolerate single-stage combined management comprising total laryngopharyngectomy with or without radical neck dissection plus ileocolic free flap reconstruction and postoperative CCRT (with one exception), without immediate morbidity or mortality.
  • Eleven patients were diagnosed with hypopharyngeal cancer and one with laryngeal cancer.
  • [MeSH-major] Colon / transplantation. Deglutition / physiology. Hypopharyngeal Neoplasms / surgery. Ileocecal Valve / transplantation. Laryngeal Neoplasms / surgery. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Speech / physiology. Surgical Flaps
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Follow-Up Studies. Humans. Laryngectomy / rehabilitation. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pharyngectomy / rehabilitation. Quality of Life. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076714.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


92. Kornek GV, Selzer E: [Organ sparing treatment modalities - which type of treatment for which carcinoma?]. Wien Med Wochenschr; 2008;158(9-10):264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ sparing treatment modalities - which type of treatment for which carcinoma?].
  • [Transliterated title] Organerhaltende Therapiemodalitäten - welche Therapie für welches Karzinom?
  • Radical surgery followed by postoperative radiotherapy is still the most effective treatment option for advanced resectable head and neck cancer.
  • It is therefore of utmost importance to determine the resectability before start of the treatment.
  • For those patients who suffer from unresectable cancer or refuse to undergo surgery, alternatives, such as induction-chemotherapy or radiotherapy plus chemotherapy alone may be offered.
  • Historical studies investigating alternative treatment protocols were conducted almost 20 years ago.
  • These studies demonstrated that in approximately 2/3 of all patients with laryngeal and hypopharyngeal cancer undergoing induction-chemotherapy according to the PF-protocol (cisplatin plus 5-FU as a continuous infusion) and subsequent radiotherapy, larynx preservation without negative impact on overall survival could be achieved.
  • At least three randomized studies have shown a clinical advantage for a treatment combination consisting of docetaxel or paclitaxel plus CDDP/5-FU over a historical control regimen containing CDDP/5-FU alone.
  • This novel combination therefore is currently regarded as the gold-standard for induction-chemotherapy in advanced head and neck cancer patients.
  • A further significant addition to the therapeutic armamentarium for the head and neck radiation oncologist is the recently introduced monoclonal antibody cetuximab.
  • It was found in a randomized landmark study that addition of cetuximab to radiotherapy significantly improves local control as well as overall survival of advanced stage head and neck cancer patients.
  • In light of these recent developments this review discusses the role of organ sparing treatment protocols and different levels of evidence with special consideration of tumor localization.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Invasiveness. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Randomized Controlled Trials as Topic. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 1998 Oct;8(4):262-9 [9873104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • (PMID = 18560952.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 17
  •  go-up   go-down


93. Lo Galbo AM, de Bree R, Kuik DJ, Lips P, Leemans CR: Paratracheal lymph node dissection does not negatively affect thyroid dysfunction in patients undergoing laryngectomy. Eur Arch Otorhinolaryngol; 2010 May;267(5):807-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1990 to 2004, 169 patients with a carcinoma of the larynx or hypopharynx who underwent paratracheal lymph node dissection were selected.
  • Patient, tumor and treatment characteristics were noted including age, gender, site, TNM stage and details of surgery, radiotherapy and chemotherapy.
  • All patients with hypo(para)thyroidism underwent various lymph node treatment modalities.
  • For the various treatment combinations, no increase of hypo(para)thyroidism was found if a bilateral paratracheal lymph node dissection was performed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Hypoparathyroidism / epidemiology. Hypoparathyroidism / physiopathology. Hypopharyngeal Neoplasms / epidemiology. Hypopharyngeal Neoplasms / therapy. Hypothyroidism / epidemiology. Hypothyroidism / physiopathology. Laryngectomy / methods. Lymph Node Excision
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Severity of Illness Index. Trachea / pathology. Trachea / radiation effects. Trachea / surgery

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2000 Jul-Aug;62(4):217-25 [10859523.001]
  • [Cites] Laryngoscope. 2005 May;115(5):894-8 [15867661.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1595-9 [12972940.001]
  • [Cites] Arch Med Res. 2006 Jan;37(1):133-9 [16314199.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):547-9 [14870783.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jul;392(4):423-6 [17131155.001]
  • [Cites] Head Neck. 2008 Mar;30(3):336-40 [17636544.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2007 Jun;27(3):123-5 [17883188.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2892-7 [11753963.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1997 Feb;22(1):7-12 [9088672.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):312-7 [17364370.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):318-22 [17364371.001]
  • [Cites] Qual Life Res. 1994 Oct;3(5):323-7 [7841966.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Apr;24(2):104-8 [10225153.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Apr;259(4):193-6 [12064507.001]
  • (PMID = 19915857.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Davis GE, Schwartz SR, Veenstra DL, Yueh B: Cost comparison of surgery vs organ preservation for laryngeal cancer. Arch Otolaryngol Head Neck Surg; 2005 Jan;131(1):21-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost comparison of surgery vs organ preservation for laryngeal cancer.
  • OBJECTIVE: To perform a cost minimization analysis of total laryngectomy with postoperative radiotherapy vs induction chemotherapy with subsequent radiotherapy in patients with advanced (stage III or IV) squamous cell carcinoma of the larynx.
  • DESIGN: Decision-analysis model using data from peer-reviewed trials, case series, meta-analyses, and Medicare diagnosis related group reimbursement rates.
  • SETTING AND PATIENTS: A hypothetical cohort of patients with stage III or IV laryngeal cancer.
  • The perspective is that of a health care payer.
  • INTERVENTIONS: The hypothetical patient cohort could receive (1) surgery (total laryngectomy) with postoperative radiotherapy or (2) induction chemotherapy (fluorouracil and cisplatin) with radiotherapy followed by salvage surgery for patients failing to respond to chemotherapy.
  • MAIN OUTCOME MEASURE: Overall difference in direct medical costs in 2003 US dollars between the 2 treatment arms from initiation to completion of treatment.
  • The finding that the surgical arm costs were lower was robust to all sensitivity analyses except for the extreme low estimate for the cost of chemotherapy.
  • CONCLUSIONS: Our results suggest that total laryngectomy with postoperative radiotherapy costs nearly 3000 US dollars less than organ preservation treatment for advanced laryngeal cancer.
  • Given that survival appears equivalent between the 2 modalities, cost consideration and patient preference may be important factors in decision making for the treatment of advanced laryngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / economics. Laryngeal Neoplasms / therapy. Laryngectomy / economics. Radiotherapy, Adjuvant / economics
  • [MeSH-minor] Antineoplastic Agents / economics. Antineoplastic Agents / therapeutic use. Cisplatin / economics. Cisplatin / therapeutic use. Costs and Cost Analysis. Decision Support Techniques. Fluorouracil / economics. Fluorouracil / therapeutic use. Humans. Models, Theoretical. Neoplasm Staging

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655180.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / ODCDC CDC HHS / CD / CD-98318; United States / NIDCD NIH HHS / DC / DC-00018
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


95. Yoo SS, Carter D, Turner BC, Sasaki CT, Son YH, Wilson LD, Glazer PM, Haffty BG: Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer; 2000 Feb 20;90(1):22-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation.
  • The purpose of the current study is to evaluate the prognostic significance of cycD1 for local recurrence in early-stage larynx cancer treated with primary radiation therapy.
  • The study was conducted using a matched case-control design in 60 early-stage (T1-T2/N0) larynx cancer patients.
  • All patients had squamous cell carcinoma of the larynx and were treated with primary radiation to a total median dose of 66 Gy in daily fractions of 2 Gy, without surgery or chemotherapy.
  • Thirty patients who suffered a local relapse in the larynx after treatment served as the index case population.
  • These 30 cases were matched by age, sex, site (glottic vs. supraglottic), radiation therapy technique/dose, and follow-up, to 30 control patients who did not experience a local relapse.
  • Patients were considered to be positive for cyclin D1 if the staining was 2+ or greater with a percent distribution of at least 5%.
  • By design of the study, the two groups were evenly balanced with respect to age, sex, stage, radiation dose, and follow-up.
  • CycD1 levels correlated with proliferating cell nuclear antigen levels.
  • These data suggest that low levels of cycD1 correlate with relatively radioresistant early-stage larynx carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Cyclin D1 / analysis. Laryngeal Neoplasms / chemistry. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry
  • [MeSH-minor] Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Radiotherapy Dosage

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10725854.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


96. Prades JM, Schmitt TM, Timoshenko AP, Simon PG, de Cornulier J, Durand M, Guillot A, Martin C: Concomitant chemoradiotherapy in pyriform sinus carcinoma. Arch Otolaryngol Head Neck Surg; 2002 Apr;128(4):384-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemoradiotherapy in pyriform sinus carcinoma.
  • OBJECTIVES: To test the effectiveness of concurrent chemoradiotherapy in patients with pyriform sinus carcinoma and to demonstrate the feasibility of an organ preservation approach.
  • SETTING: University Hospital Center, St-Etienne, France.
  • PATIENTS: The study population comprised 46 male patients with resectable stage III and IV pyriform sinus carcinoma.
  • In protocol 1 (24 patients), carboplatin was given on days 1 through 5 and 28 through 33, with an area under the curve dose of 5 mg/mL for 1 minute per day and bifractionated radiotherapy (160 rad [1.6 Gy]/fraction) delivered on days 1 through 16 and 28 through 38.
  • A treatment break was planned on days 16 through 27.
  • In protocol 2 (22 patients), chemotherapy was given with the same dose of carboplatin on days 1 and 21, and fluorouracil (750 mg/m(2) per day) on days 1 through 7 and 21 through 28.
  • Radiotherapy with a single fraction of 180 rad (1.8 Gy)/d was delivered during the first 2 weeks and then 150 rad (1.5 Gy) twice a day during the next 3 weeks.
  • After 2 years of follow up, 16 patients (67%) (protocol 1) and 12 patients (55%) (protocol 2) retained their larynx without evidence of disease.
  • During therapy, 15 patients (63%) (protocol 1) and 19 patients (86%) (protocol 2) required unplanned hospitalization for toxic effects.
  • CONCLUSION: Concomitant chemotherapy and bifractionated radiotherapy, although toxic, leads to good locoregional control and therefore to a significant level of laryngeal preservation.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy / adverse effects. Disease-Free Survival. Dose Fractionation. Fluorouracil / therapeutic use. Humans. Larynx. Male. Middle Aged. Survival Rate

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Otolaryngol Head Neck Surg. 2003 Dec;129(12):1351; author reply 1351 [14676171.001]
  • (PMID = 11926911.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


97. Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB, Nam SY, Kim SY: 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol; 2007 Aug;33(6):790-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx.
  • Pretreatment FDG uptake was evaluated as a predictor of survival and guidance for primary surgery or radiotherapy (RT) in patients with squamous cell carcinoma (SCC) of the larynx and hypopharynx.
  • MATERIALS AND METHODS: Seventy-nine consecutive patients with newly diagnosed advanced resectable SCC of the larynx and hypopharynx underwent FDG positron emission tomography (PET) before surgical resection plus RT and chemotherapy (surgery group, n=40) or RT with chemotherapy and surgical salvage (RT group, n=39).
  • Age, tumor stage, histological grade, treatment strategy, and standardized uptake value (SUV) were analyzed for association with local control and survival.
  • When patients with SUV>8.0 in the two treatment groups were analyzed separately, those in the surgery group tended to have a higher 3-year DFS than those in the RT group, despite no statistical significance (48% vs. 27%, P=0.085).
  • Patients with high FDG uptake may be better treated by surgical resection followed by RT and chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Fluorodeoxyglucose F18. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / surgery. Patient Care Planning. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Forecasting. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Radiotherapy, Adjuvant. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306956.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. van den Broek GB, Rasch CR, Pameijer FA, Peter E, van den Brekel MW, Tan IB, Schornagel JH, de Bois JA, Zijp LJ, Balm AJ: Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer; 2004 Oct 15;101(8):1809-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
  • BACKGROUND: Concurrent chemoradiation is being used increasingly to treat patients with advanced-stage head and neck carcinoma.
  • In the current study, a clinical nomogram was developed to predict local control and overall survival rates for individual patients who will undergo chemoradiation.
  • METHODS: Ninety-two consecutive patients with UICC TNM Stage III/IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and supraglottic larynx were treated with selective-targeted chemoradiation (acronym: RADPLAT).
  • Using tumor volume as a continuous variable, an adjusted risk ratio of 1.026 was found, indicating that each 1-cm(3) increase in volume was associated with a 2.6% decrease in probability of local control.
  • CONCLUSIONS: Tumor volume was found to play a significant role in predicting local control and overall survival in patients with advanced-stage head and neck carcinoma who were treated with targeted chemoradiation.
  • The nomograms may be useful for pretreatment selection of patients with advanced-stage head and neck carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Lymph Nodes / pathology. Male. Middle Aged. Models, Biological. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Probability. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386309.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


99. Jo S, Juhasz A, Zhang K, Ruel C, Loera S, Wilczynski SP, Yen Y, Liu X, Ellenhorn J, Lim D, Paz B, Somlo G, Vora N, Shibata S: Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res; 2009 May;29(5):1467-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.
  • The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1alpha and VEGF expression in HPV-positive and -negative tumors.
  • PATIENTS AND METHODS: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx.
  • HIF-1alpha and VEGF expression were assessed by quantitative real-time PCR (RT-PCR).
  • There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively.
  • CONCLUSION: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Surg. 1983 Dec;12(6):418-24 [6325356.001]
  • [Cites] EMBO J. 1988 Jun;7(6):1815-20 [2458921.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):153-9 [11943893.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jul;125(1):1-9 [11458206.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):401-3 [11328843.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4611-20 [11030150.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):300-4 [10861508.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):117-23 [10585594.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2568-76 [17473185.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1418-25 [17205528.001]
  • [Cites] Cell Mol Life Sci. 2006 Apr;63(7-8):930-8 [16596339.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2558-64 [16314836.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):206-13 [15790460.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):775-82 [10213212.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):755-62 [9816227.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):145-56 [9422532.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):513-6 [9158399.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):595-604 [9028373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3187-92 [12374687.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2620-6 [12855639.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):394-400 [14506739.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):766-72 [14696105.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):468-71 [14744758.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):418-23 [15091212.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006 [15240783.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3061-9 [15284256.001]
  • (PMID = 19443352.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS431020; NLM/ PMC3582681
  •  go-up   go-down


100. Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, Fu KK: Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.
  • PURPOSE: To review the UCSF-SUH experience in the treatment of advanced T3--4 laryngeal carcinoma and to evaluate the different factors affecting locoregional control and survival.
  • METHODS AND MATERIALS: We reviewed the records of 223 patients treated for T3--4 squamous cell carcinoma of the larynx between October 1, 1957, and December 1, 1999.
  • There were 187 men and 36 women, with a median age of 60 years (range, 28--85 years).
  • We retrospectively staged the patients according to the 1997 AJCC staging system.
  • The overall stage was III in 93 and IV in 130 patients.
  • Surgery was the primary treatment modality in 161 patients, of which 134 had postoperative radiotherapy (RT), 11 had preoperative RT, 7 had surgery followed by RT and chemotherapy (CT), and 9 had surgery alone.
  • Significant prognostic factors for LRC on univariate analysis were primary site, N stage, overall stage, the lowest hemoglobin (Hgb) level during RT, and treatment modality.
  • Favorable prognostic factors for LRC on multivariate analysis were lower N stage and primary surgery.
  • Significant prognostic factors for OS on univariate analysis were: primary site, age, overall stage, T stage, N stage, lowest Hgb level during RT, and treatment modality.
  • Favorable prognostic factors for OS on multivariate analysis were lower N stage and higher Hgb level during RT.
  • CONCLUSION: Lower N-stage was a favorable prognostic factor for LRC and OS.
  • Correcting the Hbg level before and during treatment should be investigated in future clinical trials as a way of improving therapeutic outcome in patients with advanced laryngeal carcinomas.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. California / epidemiology. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Hemoglobins / analysis. Humans. Laryngectomy / adverse effects. Life Tables. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Radiotherapy, Adjuvant / adverse effects. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483326.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement